var title_f31_55_32624="Peripheral IV placement 3";
var content_f31_55_32624=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral IV placement: Local anaesthetic",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A subcutaneous wheal of local anesthetic (eg, 1 percent lidocaine) may be placed over the venipuncture site to reduce pain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Frank, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32624=[""].join("\n");
var outline_f31_55_32624=null;
var title_f31_55_32625="Skin burns";
var content_f31_55_32625=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Skin burns (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/55/32625/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32625/contributors\" id=\"au5743\">",
"       Eric D Morgan, MD, MPH",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32625/contributors\" id=\"au6268\">",
"       William F Miser, MD, MA",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/55/32625/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32625/contributors\" id=\"se7269\">",
"       Ron M Walls, MD, FRCPC, FAAEM",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/55/32625/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32625/contributors\" id=\"de97\">",
"       Jonathan Grayzel, MD, FAAEM",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/55/32625?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SKIN BURNS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Skin burn injuries are common, with over one million burn injuries occurring every year in the United States. Skin burns can result from exposure to several possible sources, including hot water or steam, hot objects or flames, chemicals, electricity, or overexposure to the sun.",
"    </p>",
"    <p>",
"     Most skin burns are minor and can be managed at home. However, it is important to know the signs of a more serious skin burn, which should be evaluated and treated by a healthcare provider. Moderate to severe burns can cause a number of serious complications and usually require urgent treatment.",
"    </p>",
"    <p>",
"     This article discusses skin burns caused by steam, hot water or other hot objects in the home, including which burns can be treated at home and those that require evaluation and treatment by a healthcare provider. Other topics that discuss burns are also available. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=see_link\">",
"      \"Emergency care of moderate and severe thermal burns in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37479?source=see_link\">",
"      \"Treatment of minor thermal burns\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11801?source=see_link\">",
"      \"Topical chemical burns\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4410?source=see_link\">",
"      \"Environmental electrical injuries\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SKIN BURN SYMPTOMS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      When to seek help",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have any of the following, you should call your healthcare provider.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       If the burn involves the face, hands or fingers, genitals, or feet",
"      </li>",
"      <li>",
"       If the burn is on or near a joint (knee, shoulder, hip)",
"      </li>",
"      <li>",
"       If the burn encircles a body part (arm, leg, foot, chest, finger)",
"      </li>",
"      <li>",
"       If the burn is large (greater than 3 inches or 7.5 cm) or deep (deep partial-thickness or full thickness) (see",
"       <a class=\"local\" href=\"#H4\">",
"        'Burn type'",
"       </a>",
"       below)",
"      </li>",
"      <li>",
"       If the victim is young (less than five years) or older than 70 years",
"      </li>",
"      <li>",
"       If there are signs of skin infection, such as increasing redness, pain, pus-like discharge, or temperature greater than 100.4&ordm;F or 38&ordm;C",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Burn type",
"     </span>",
"     &nbsp;&mdash;&nbsp;Burns were previously classified as first, second, third, or fourth degree, based on the thickness of the skin burned. This system is being replaced with a system that better describes which burns require surgical treatment.",
"    </p>",
"    <p>",
"     The classification of a burn can change over the first few days. This means that a burn may appear superficial initially, then become deeper over time. If you are unsure how deeply your skin is burned, contact a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Superficial skin burns",
"     </span>",
"     &nbsp;&mdash;&nbsp;Superficial skin burns, previously called first-degree burns, involve only the top layer of skin, are painful, dry, and red, and turn white when pressed (",
"     <a class=\"graphic graphic_picture graphicRef60417 \" href=\"mobipreview.htm?27/8/27790\">",
"      picture 1",
"     </a>",
"     ). Superficial burns generally heal in three to six days without scarring. Non-blistering sunburns are a good example of a superficial skin burn.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Superficial partial-thickness skin burns",
"     </span>",
"     &nbsp;&mdash;&nbsp;Superficial partial-thickness skin burns, previously called second-degree burns, involve the top two layers of skin, are painful with air movement or air temperature changes, are red and seep fluid, usually form blisters, and turn white when pressed (",
"     <a class=\"graphic graphic_picture graphicRef65552 \" href=\"mobipreview.htm?19/18/19744\">",
"      picture 2",
"     </a>",
"     ). Superficial partial thickness skin burns heal within seven to 21 days. The burned area may permanently become darker or lighter in color but a scar does not usually form.",
"    </p>",
"    <p>",
"     Sunburns that blister after several hours are good examples of superficial partial-thickness burns.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Deep partial-thickness skin burns",
"     </span>",
"     &nbsp;&mdash;&nbsp;Deep partial-thickness skin burns, previously called third-degree burns, extend deeper into the skin, are painful with deep pressure, almost always form blisters, and do not turn white with pressure. Deep partial-thickness skin burns take more than 21 days to heal and usually develop a scar, which may be severe.",
"    </p>",
"    <p>",
"     Burns that blister immediately are deep partial-thickness burns. A blister that persists for several weeks is also considered a deep partial-thickness burn.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Full-thickness burns",
"     </span>",
"     &nbsp;&mdash;&nbsp;Full-thickness skin burns, previously called fourth-degree burns, extend through all layers of the skin, completely destroying the skin. The burned area usually does not hurt, is a waxy white to leathery gray or charred black color, and the skin is dry and does not blanch when touched (",
"     <a class=\"graphic graphic_picture graphicRef63587 \" href=\"mobipreview.htm?2/12/2240\">",
"      picture 3",
"     </a>",
"     ). Full-thickness burns cannot heal without surgical treatment and scarring is usually severe.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      SKIN BURN TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Small superficial or superficial partial-thickness burns can often be treated at home. However, burns that are larger or deeper should be evaluated by a healthcare provider.",
"    </p>",
"    <p>",
"     Home treatment of skin burns should include cleaning the area, immediately cooling it, preventing infection, and managing pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Clean the area",
"     </span>",
"     &nbsp;&mdash;&nbsp;Remove any clothing from the burned area. If clothing is stuck to the skin, do not try to remove it and seek emergency medical care.",
"    </p>",
"    <p>",
"     Wash the burned skin gently with cool tap water and plain soap. It is not necessary to disinfect the skin with alcohol, iodine, or other cleansers.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Cool the area",
"     </span>",
"     &nbsp;&mdash;&nbsp;After cleaning the skin, you may apply a cold compress to the skin or soak the area in cool water to reduce pain and reduce the extent of the burn. Avoid placing ice directly on the skin because this can damage the skin further.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Prevent infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;To prevent infection in partial-thickness and more severe burns, apply aloe vera or an antibiotic cream, such as bacitracin. Do not apply ointments or other substances to skin burns.",
"    </p>",
"    <p>",
"     Minor burns may be covered with a bandage or dressing if you wish; burns that form blisters should be covered with a clean bandage or dressing. A bandage that does not stick to the skin (labeled as \"non-stick\") is preferred for the first layer. Change the dressing once or twice per day, as needed.",
"    </p>",
"    <p>",
"     Do not try to break open skin blisters with a needle or fingernail because this can increase the risk of skin infection. The blister will open and drain on its own.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Tetanus prevention",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have not had a tetanus shot in the past five years and your burn is superficial partial-thickness or deeper, you need a tetanus booster vaccine. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"      \"Patient information: Adult vaccines (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Treat pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Elevating burns on the hand or foot above the level of the heart can help to prevent swelling and pain.",
"    </p>",
"    <p>",
"     You may take a non-prescription pain medication, such as acetaminophen (eg, Tylenol&reg;) or ibuprofen (Advil&reg;, Motrin&reg;) if needed for pain. If your pain is not controlled with these medications, contact your healthcare provider. People with more severe or larger burns may require a prescription pain medication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Avoid scratching the skin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people are bothered by itching as the burned skin begins to heal. Try to avoid scratching the skin. Use a moisturizing lotion if needed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      SKIN BURN FOLLOW UP",
"     </span>",
"    </p>",
"    <p>",
"     If your burn is not healing, becomes more painful, or appears infected, you should see a healthcare provider.",
"    </p>",
"    <p>",
"     Most skin burns that are small and superficial will heal within one week and will not usually scar. After a superficial partial-thickness burn, the skin may become darker or lighter in color, but will not usually scar.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      PREVENTING SKIN BURNS",
"     </span>",
"    </p>",
"    <p>",
"     Skin burns can often be prevented by making some changes in your home.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Keep lit candles, matches, and lighters out of the reach of children. Do not smoke when sleepy or after taking sedatives or sleeping pills.",
"      </li>",
"      <li>",
"       Keep hot foods and drinks, irons, and curling irons away from the edge of counters and tables.",
"      </li>",
"      <li>",
"       Use a cool-mist humidifier rather than a warm mist or steam humidifier.",
"      </li>",
"      <li>",
"       Keep children away from hot stoves, fireplaces, and ovens. Turn pot handles inward and cook on the rear burners when possible. Never carry a child in your arms while cooking.",
"      </li>",
"      <li>",
"       Install a smoke detector on each floor of your home. Test the batteries in smoke detectors once per month and change if needed.",
"      </li>",
"      <li>",
"       Children's sleepwear should be non-flammable. Sweat pants and loose t-shirts are not as safe as sleepwear. Cotton sleepwear should fit snugly.",
"      </li>",
"      <li>",
"       Set the thermostat on your hot water heater no higher than 120&ordm;F (49&ordm;C). If you cannot adjust your hot water heater, install an anti-scald device on your shower, bath, or faucet.",
"      </li>",
"      <li>",
"       Cover car seats, seat belts, and strollers with a blanket or towel if you must leave them in a parked car on a hot day. Be careful when placing the child in the seat because metal and vinyl can become very hot.",
"      </li>",
"      <li>",
"       Prevent sunburn by applying sunscreen liberally and staying out of the sun when possible. Sunburn prevention is discussed in detail separately. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/60/33729?source=see_link\">",
"        \"Patient information: Sunburn prevention (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284225\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284248\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/20/23874?source=see_link\">",
"      Patient information: Sunburn (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/43/25266?source=see_link\">",
"      Patient information: Skin burns (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/9/32913?source=see_link\">",
"      Patient information: Acute compartment syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/51/33586?source=see_link\">",
"      Patient information: Electrical burns (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/60/5058?source=see_link\">",
"      Patient information: Blisters (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284232\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/60/33729?source=see_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284364\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=see_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4410?source=see_link\">",
"      Environmental electrical injuries",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11801?source=see_link\">",
"      Topical chemical burns",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37479?source=see_link\">",
"      Treatment of minor thermal burns",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Kids Health",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidshealth.org/parent/firstaid_safe/emergencies/burns.html\">",
"      file://kidshealth.org/parent/firstaid_safe/emergencies/burns.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Burn Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ameriburn.org/\">",
"      www.ameriburn.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Medline Plus",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000030.htm\">",
"      file://www.nlm.nih.gov/medlineplus/ency/article/000030.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/55/32625/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/55/32625?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32625/abstract/1\">",
"      Lowell G, Quinlan K, Gottlieb LJ. Preventing unintentional scald burns: moving beyond tap water. Pediatrics 2008; 122:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32625/abstract/2\">",
"      Turner C, Spinks A, McClure R, Nixon J. Community-based interventions for the prevention of burns and scalds in children. Cochrane Database Syst Rev 2004; :CD004335.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f31_55_32625=[""].join("\n");
var outline_f31_55_32625=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SKIN BURNS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SKIN BURN SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           SKIN BURN TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           SKIN BURN FOLLOW UP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           PREVENTING SKIN BURNS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/8/27790\" title=\"picture 1\">",
"           Superficial burn PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/18/19744\" title=\"picture 2\">",
"           Partial thickness burn PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/12/2240\" title=\"picture 3\">",
"           Full thickness burn PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f31_55_32626="Angioedema lip and tongue PI";
var content_f31_55_32626=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Angioedema of the lips and tongue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 221px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Angioedema causes puffiness of the tissues under the skin, often in the face. These photos show angioedema that affects the lips (A) and one side of the tongue (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32626=[""].join("\n");
var outline_f31_55_32626=null;
var title_f31_55_32627="Chronic pelvic pain in women";
var content_f31_55_32627=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Chronic pelvic pain in women (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/55/32627/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32627/contributors\" id=\"au4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/55/32627/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32627/contributors\" id=\"se60\">",
"       Linda Brubaker, MD, FACS, FACOG",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/55/32627/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32627/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/55/32627?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CHRONIC PELVIC PAIN DEFINITION",
"     </span>",
"    </p>",
"    <p>",
"     Chronic pelvic pain is defined as pain that occurs below the umbilicus (belly button) that lasts for at least six months. It may or may not be associated with menstrual periods. Chronic pelvic pain is often a symptom that can be caused by several different conditions, but is sometimes a chronic condition due to abnormal function of the nervous system (often called &ldquo;neuropathic pain&rdquo;).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CAUSES OF CHRONIC PELVIC PAIN",
"     </span>",
"    </p>",
"    <p>",
"     A variety of gynecologic, gastrointestinal, and bodywide disorders can cause chronic pelvic pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Gynecologic causes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gynecologic causes are thought to be the cause of chronic pelvic pain in about 20 percent of women. Some of the gynecologic causes of pelvic pain include:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Endometriosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;The tissue lining the inside of the uterus is called the endometrium (",
"     <a class=\"graphic graphic_figure graphicRef80271 \" href=\"mobipreview.htm?14/52/15171\">",
"      figure 1",
"     </a>",
"     ). Endometriosis is a condition in which endometrial tissue is also present outside of the uterus. Some women with endometriosis have no symptoms, while others experience marked discomfort and pain and may have problems with fertility. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/63/26611?source=see_link\">",
"      \"Patient information: Endometriosis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=see_link\">",
"      \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Chronic pelvic inflammatory disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pelvic inflammatory disease is an acute infection usually caused by a sexually transmitted organism. Occasionally, it is caused by a ruptured appendix, tuberculosis, or diverticulitis. It can involve the uterus, ovaries, and fallopian tubes (which link the ovaries and uterus) (",
"     <a class=\"graphic graphic_figure graphicRef80271 \" href=\"mobipreview.htm?14/52/15171\">",
"      figure 1",
"     </a>",
"     ). Chronic pelvic inflammatory disease occurs after acute pelvic inflammatory disease in about one-third of women and causes chronic pelvic pain. The reason for this is not clearly known, but is likely because of permanent damage to the uterus, ovaries, and fallopian tubes. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/44/1730?source=see_link\">",
"      \"Patient information: Gonorrhea (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=see_link\">",
"      \"Patient information: Chlamydia (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Other causes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Non-gynecologic causes of chronic pelvic pain may be related to the digestive system, urinary system, or to pain in the muscles and nerves in the pelvis:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Irritable bowel syndrome",
"     </span>",
"     &nbsp;&mdash;&nbsp;Irritable bowel syndrome is a gastrointestinal condition characterized by chronic abdominal pain and altered bowel habits (such as loose stools, more frequent bowel movements with onset of pain, and pain relieved by defecation) in the absence of any specific cause. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/53/3926?source=see_link\">",
"      \"Patient information: Irritable bowel syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Painful bladder syndrome and interstitial cystitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Painful bladder syndrome and interstitial cystitis",
"     <span class=\"nowrap\">",
"      (PBS/IC)",
"     </span>",
"     are the terms given to bladder pain that is not caused by infection. Symptoms usually include the need to urinate frequently (frequency) and a feeling of urgently needing to urinate (urgency). Some women with painful bladder syndrome have lower abdominal or pelvic pain in addition to urinary tract symptoms. A separate topic review is available that discusses",
"     <span class=\"nowrap\">",
"      PBS/IC.",
"     </span>",
"     (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/48/31490?source=see_link\">",
"      \"Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Diverticulitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;A diverticulum is a sac-like protrusion that sometimes forms in the muscular wall of the colon (or intestine). Diverticulitis occurs when diverticula become inflamed. This usually causes abdominal pain; nausea and vomiting, constipation, diarrhea, and urinary symptoms can also occur. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/32/17922?source=see_link\">",
"      \"Patient information: Diverticular disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Pelvic floor pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Symptoms of pelvic floor dysfunction may include pelvic pain, pain with urination, difficulty urinating, constipation, pain with intercourse, or",
"     <span class=\"nowrap\">",
"      frequent/urgent",
"     </span>",
"     urination. Pelvic floor dysfunction can be diagnosed by a clinician feeling the pelvic floor muscles (muscles that support the pelvic organs and hips) through the vagina",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     rectum; muscles that feel tight, tender, or band-like indicate that pelvic floor dysfunction could be contributing to pelvic pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24187354\">",
"     <span class=\"h3\">",
"      Abdominal myofascial pain (trigger points)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pain can originate from the muscles of the abdominal wall due to myofascial pain. This problem usually has small localized areas of abnormal tenderness of the abdominal muscles that are called trigger points. Abdominal myofascial pain is diagnosed by the clinician examining the abdominal muscles for trigger points; often tightening of these muscles while they are examined causes increased pain and assists in diagnosis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Fibromyalgia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fibromyalgia is one of a group of chronic pain disorders that affect connective tissue structures, including muscles, ligaments, and tendons. It is characterized by widespread muscle pain (or \"myalgia\") and tenderness in certain areas of the body. Women with fibromyalgia may also experience fatigue, sleep disturbances, headaches, and mood disturbances such as depression and anxiety. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=see_link\">",
"      \"Patient information: Fibromyalgia (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      DIAGNOSIS OF THE CAUSE OF CHRONIC PELVIC PAIN",
"     </span>",
"    </p>",
"    <p>",
"     Because a number of different conditions can cause chronic pelvic pain, it is sometimes difficult to pinpoint the specific cause.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      History and physical examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;A thorough history and a physical examination of the abdomen and pelvis are essential components of the work-up for women with pelvic pain. In particular, the examination should include the lower back, abdomen, hips, and pelvis (internal examination).",
"    </p>",
"    <p>",
"     Laboratory tests, including a white blood cell count, urinalysis, tests for sexually transmitted infections, and a pregnancy test may be recommended, depending upon the results of the physical examination.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Pelvic ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some diagnostic procedures may also be helpful in identifying the cause of chronic pelvic pain. As an example, a pelvic ultrasound examination is accurate in detecting pelvic masses, including ovarian cysts (sometimes caused by ovarian endometriosis) and uterine fibroids. However, ultrasound is not helpful in the diagnosis of irritable bowel syndrome, diverticulitis, or painful bladder syndrome.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Laparoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A surgical procedure called a laparoscopy may be helpful in diagnosing some causes of chronic pelvic pain such as endometriosis and chronic pelvic inflammatory disease. Laparoscopy is a procedure that is often done as a day surgery. Most women are given general anesthesia to induce sleep and prevent pain. A thin telescope with a camera is inserted through a small incision just below the navel. Through the telescope, the surgeon can see the contents of the abdomen, especially the reproductive organs. If the laparoscopy is normal, the physician can then focus the diagnostic and treatment efforts on non-gynecologic causes of pelvic pain.",
"    </p>",
"    <p>",
"     If the laparoscopy is abnormal (eg, areas of endometriosis or abnormal tissue are seen) these areas may be treated or biopsied during the procedure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      COPING WITH CHRONIC PELVIC PAIN",
"     </span>",
"    </p>",
"    <p>",
"     Psychological counseling may be offered to help women manage their pelvic pain. There are several types of psychosocial support:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Psychotherapy involves meeting with a psychologist, psychiatrist, or social worker to discuss emotional responses to living with chronic pain, treatment successes or failures,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       personal relationships.",
"      </li>",
"      <li>",
"       Group psychotherapy allows people to compare their experiences with",
"       <span class=\"nowrap\">",
"        PBS/IC,",
"       </span>",
"       overcome the tendency to withdraw and become isolated in pain, and support one another's attempts at more effective management.",
"      </li>",
"      <li>",
"       Online or local support groups that deal with chronic pain may also be helpful, such as the American Chronic Pain Society (",
"       <a class=\"external\" href=\"file://www.theacpa.org/\">",
"        www.theacpa.org",
"       </a>",
"       ) and the American Academy of Pain Management (",
"       <a class=\"external\" href=\"file://www.aapainmanage.org/links/Links.php\">",
"        www.aapainmanage.org/links/Links.php",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Relaxation techniques can relieve musculoskeletal tension, and may include meditation, progressive muscle relaxation, self-hypnosis, or biofeedback.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      CHRONIC PELVIC PAIN TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Chronic pelvic pain due to a gynecologic condition is often treated medically. In some cases, however, surgery may be the treatment of choice.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Medical treatment",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       One approach to managing women with chronic pelvic pain is to prescribe sequential drug treatments for disorders that are the most likely causes of the patient's pain. As an example, endometriosis is the most common gynecological cause of chronic pelvic pain. If endometriosis seems a likely diagnosis based upon the history and physical examination, then a medical therapy for endometriosis is given for a trial period. If this is not successful, then a trial of another medical therapy is initiated. If one of these treatments relieves the pelvic pain, then the likelihood that endometriosis is the cause of pain increases. However, it is important to note that improvement in symptoms is not absolute confirmation of a diagnosis since treatment effects are often not specific. As an example, hormonal treatment of endometriosis may also improve pelvic congestion syndrome, irritable bowel syndrome, or interstitial",
"       <span class=\"nowrap\">",
"        cystitis/painful",
"       </span>",
"       bladder syndrome",
"      </li>",
"      <li>",
"       A different approach is to use intensive diagnostic testing in an attempt to identify the specific cause of the patient's pain, if possible, before starting specific therapy. Although therapy targeted specifically to the patient's diagnosis might appear ideal, arriving at a diagnosis may involve costly laboratory and imaging tests, and often requires exploratory surgery.",
"      </li>",
"      <li>",
"       A third option is treatment directed at pain, rather than at a specific diagnosis. Nonsteroidal anti-inflammatory drugs, antidepressants, and anticonvulsive medications are often used.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Physical therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pelvic floor physical therapy (PT) is often helpful for women with abdominal myofascial pain and with pelvic floor pain. This type of PT aims to release the tightness in these muscles by manually \"releasing\" the tightness; treatment is directed to the muscles in the abdomen, vagina, hips, thighs, and lower back. Physical therapists who perform this type of PT must be specially trained. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/22/17764?source=see_link\">",
"      \"Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Pain management clinics",
"     </span>",
"     &nbsp;&mdash;&nbsp;If medications are not effective in treating the pain, a woman may be referred to a medical practice specializing in pain management. Pain services utilize multiple treatment modalities including",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Acupuncture",
"      </li>",
"      <li>",
"       Biofeedback and relaxation therapies",
"      </li>",
"      <li>",
"       Nerve stimulation devices",
"      </li>",
"      <li>",
"       Injection of tender sites with a local anesthetic (eg, lidocaine, Marcaine)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Pain services can help women who are on opioids or narcotics for pain management.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Surgical treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;A few causes of gynecologic pelvic pain can be treated surgically. For example, some women benefit from surgical removal of their endometriosis.",
"    </p>",
"    <p>",
"     Hysterectomy may alleviate chronic pelvic pain, especially when it is due to uterine disorders such as adenomyosis or fibroids. However, pain can persist even after hysterectomy, particularly in younger women (those less than 30) and in women with a history of chronic pelvic inflammatory disease or pelvic floor dysfunction. Hysterectomy is not a good choice for the management of chronic pelvic pain in women who have not completed their family. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/16/6405?source=see_link\">",
"      \"Patient information: Abdominal hysterectomy (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/48/34564?source=see_link\">",
"      \"Patient information: Vaginal hysterectomy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Surgery to cut some of the nerves in the pelvis (presacral neurectomy) has also been studied as a treatment for chronic pelvic pain. However, this approach has shown effectiveness mostly for endometriosis pain and has additional surgical risks, so it is not recommended for most women.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27016698\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27016705\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/23/42353?source=see_link\">",
"      Patient information: Chronic pelvic pain in women (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/8/5251?source=see_link\">",
"      Patient information: Endometriosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/25/11666?source=see_link\">",
"      Patient information: Painful periods (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/14/26850?source=see_link\">",
"      Patient information: Pelvic inflammatory disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27016749\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/63/26611?source=see_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=see_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/44/1730?source=see_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=see_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/53/3926?source=see_link\">",
"      Patient information: Irritable bowel syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/48/31490?source=see_link\">",
"      Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/32/17922?source=see_link\">",
"      Patient information: Diverticular disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/17/24854?source=see_link\">",
"      Patient information: Fibromyalgia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/22/17764?source=see_link\">",
"      Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/16/6405?source=see_link\">",
"      Patient information: Abdominal hysterectomy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/48/34564?source=see_link\">",
"      Patient information: Vaginal hysterectomy (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27016763\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/26/41384?source=see_link\">",
"      Causes of chronic pelvic pain in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17720?source=see_link\">",
"      Chronic prostatitis/chronic pelvic pain syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8330?source=see_link\">",
"      Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31864?source=see_link\">",
"      Evaluation of chronic pelvic pain in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39879?source=see_link\">",
"      Primary dysmenorrhea in adult women: Clinical features and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28969?source=see_link\">",
"      Treatment of chronic pelvic pain in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43369?source=see_link\">",
"      Management of interstitial cystitis/bladder pain syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28233?source=see_link\">",
"      Treatment of primary dysmenorrhea in adult women",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The International Pelvic Pain Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.pelvicpain.org/\">",
"      www.pelvicpain.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Mayo Clinic",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.mayoclinic.com/\">",
"      www.mayoclinic.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       US Department of Health and Social Services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://womenshealth.gov/\">",
"      womenshealth.gov/",
"     </a>",
"     , search for pelvic pain)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/55/32627/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/55/32627?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32627/abstract/1\">",
"      Mathias SD, Kuppermann M, Liberman RF, et al. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol 1996; 87:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32627/abstract/2\">",
"      Scialli AR. Evaluating chronic pelvic pain. A consensus recommendation. Pelvic Pain Expert Working Group. J Reprod Med 1999; 44:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32627/abstract/3\">",
"      Flor H, Fydrich T, Turk DC. Efficacy of multidisciplinary pain treatment centers: a meta-analytic review. Pain 1992; 49:221.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f31_55_32627=[""].join("\n");
var outline_f31_55_32627=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CHRONIC PELVIC PAIN DEFINITION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CAUSES OF CHRONIC PELVIC PAIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           DIAGNOSIS OF THE CAUSE OF CHRONIC PELVIC PAIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           COPING WITH CHRONIC PELVIC PAIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           CHRONIC PELVIC PAIN TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\" title=\"figure 1\">",
"           Female anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f31_55_32628="Praziquantel: Pediatric drug information";
var content_f31_55_32628=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Praziquantel: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?25/16/25860?source=see_link\">",
"    see \"Praziquantel: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/16/24836?source=see_link\">",
"    see \"Praziquantel: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Biltricide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F212674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Biltricide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anthelmintic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/16/25860?source=see_link\">",
"      see \"Praziquantel: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Flukes:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Clonorchiasis [",
"     <i>",
"      Clonorchis sinesis",
"     </i>",
"     (Chinese liver fluke)]; Opisthorchiasis [Opisthorchis viverrini (Southeast Asian liver fluke)]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling:  Children &ge;4 years and Adolescents: 25 mg/kg/dose 3 times daily (at 4- to 6-hour intervals) for 1 day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternative dosing (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009):  25 mg/kg/dose 3 times daily for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Fasciolopsis buski, Heterophyes heterophyes, Metagonimus yokogawi",
"     </i>",
"     (intestinal flukes);",
"     <i>",
"      Metorchis conjunctus",
"     </i>",
"     (North American liver fluke): 25 mg/kg/dose 3 times daily for 1 day (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Nanophyetus salmincola:",
"     </i>",
"     20 mg/kg/dose 3 times daily for 1 day (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Paragonimus westermani",
"     </i>",
"     (lung fluke): 25 mg/kg/dose 3 times daily for 2 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Schistosomiasis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: Children &gt;4 years and Adolescents: 20 mg/kg/dose 3 times daily (at 4- to 6-hour intervals) for 1 day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternative dosing (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009):",
"     <b>",
"      Note:",
"     </b>",
"     Praziquantel does not kill developing worms; therapy started within 1-2 months of exposure should be repeated in 1-2 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      S. mansoni, S. haematobium",
"     </i>",
"     : 20 mg/kg/dose twice daily for 1 day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      S. japonicum, S. mekongi",
"     </i>",
"     : 20 mg/kg/dose 3 times daily for 1 day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Tapeworms",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cysticercosis [",
"     <i>",
"      Taenia solium",
"     </i>",
"     (pork tapeworm)]; tissue (larvae) stage: 33.3 mg/kg/dose 3 times daily for 1 day followed by 16.7 mg/kg/dose 3 times daily for 29 days;",
"     <b>",
"      Note:",
"     </b>",
"     May be used in conjunction with antiseizure medication and/or corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Diphyllobothrium latum",
"     </i>",
"     (fish),",
"     <i>",
"      Taenia saginata",
"     </i>",
"     (beef),",
"     <i>",
"      Taenia solium",
"     </i>",
"     (pork),",
"     <i>",
"      Dipylidium caninum",
"     </i>",
"     (dog); intestinal (adult) stage: 5-10 mg/kg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Hymenolepis nana",
"     </i>",
"     (dwarf tapeworm): 25 mg/kg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Schistosomiasis:",
"     </b>",
"     20 mg/kg/dose 3 times daily (at 4- to 6-hour intervals) for 1 day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Clonorchiasis/opisthorchiasis:",
"     </b>",
"     25 mg/kg/dose 3 times daily (at 4- to 6-hour intervals) for 1 day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustments are recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustments in hepatic impairment:",
"     </b>",
"     Moderate to severe impairment (Child-Pugh classes B and C): Use caution; decreased metabolism may lead to higher and prolonged serum concentrations; there are no dosage adjustments provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biltricide&reg;: 600 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer tablets with water during meals; tablets can be halved or quartered; do not chew tablets due to bitter taste",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13313083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at &lt;30&deg;C (&lt;86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of all stages of schistosomiasis caused by",
"     <i>",
"      Schistosoma",
"     </i>",
"     species pathogenic to humans; treatment of clonorchiasis, opisthorchiasis (FDA approved in ages &ge;4 years and adults); has also been used in the treatment of cysticercosis and many intestinal tapeworm and trematode infections",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F212706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, anorexia, arrhythmia, AV block, bloody diarrhea, bradycardia, ectopic rhythms, eosinophilia, hypersensitivity, liver enzymes increased, myalgia, polyserositis, pruritus, seizure, somnolence, ventricular fibrillation, vertigo, vomiting, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to praziquantel or any component; ocular cysticercosis; spinal cysticercosis (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009); concurrent use with strong CYP3A4 inducers, particularly rifampin",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with moderate to severe hepatic disease (Child-Pugh class B and C) and in patients with heart abnormalities. CSF reaction syndrome in patients being treated for neurocysticercosis has been reported; syndrome includes CSF protein concentrations increased, headache, hyperthermia, intracranial hypertension, and seizures; patients with cerebral cysticercosis should be hospitalized for the duration of treatment. Not recommended for use in patients with a history of epilepsy and/or signs of potential CNS involvement suggestive of cysticercosis.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13313078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic concentrations of praziquantel may not be achieved with concurrent administration of strong inducers of cytochrome P450 (eg, rifampin); concurrent use is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F212694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the serum concentration of Anthelmintics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Praziquantel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Praziquantel. Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Praziquantel. Management: Praziquantel dose may need to be reduced when used with ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13313082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Grapefruit juice increases praziquantel peak serum concentration and AUC by 60% and 90%, respectively.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10822164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects have not been observed in animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. Use in pregnant women only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the cell permeability to calcium in schistosomes; causes strong contractions and paralysis of worm musculature leading to detachment of suckers from the blood vessel walls and to dislodgment",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: &sim;80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: CSF concentration is 14% to 20% of plasma concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &sim;80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive first-pass effect; metabolized by the liver to hydroxylated and conjugated metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 0.8-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolites: 4.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Praziquantel and metabolites excreted mainly in urine 80% (&gt;99% as metabolites)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/16/24836?source=see_link\">",
"      see \"Praziquantel: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take tablets with water during meals; do not chew. Avoid alcohol (increased CNS depression); may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      King CH and Mahmoud AA, &ldquo;Drug Five Years Later: Praziquantel,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1989, 110(4):290-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/55/32628/abstract-text/2643915 /pubmed\" id=\"2643915 \" target=\"_blank\">",
"        2643915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu LX and Weller PF, &ldquo;Antiparasitic Drug,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(18):1178-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/55/32628/abstract-text/ 8602186 /pubmed\" id=\" 8602186 \" target=\"_blank\">",
"        8602186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12721 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32628=[""].join("\n");
var outline_f31_55_32628=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212673\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212674\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049480\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049475\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212657\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212644\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049483\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313083\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049482\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212706\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049486\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049474\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313078\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212694\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212653\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313082\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212654\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10822164\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049473\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049485\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049479\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12721\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12721|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/16/25860?source=related_link\">",
"      Praziquantel: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/16/24836?source=related_link\">",
"      Praziquantel: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_55_32629="Pheo in adrenal gland";
var content_f31_55_32629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F85629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F85629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pheochromocytoma in an accessory adrenal gland: Surgical specimen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multicentric pheochromocytoma of the left adrenal gland together with a small pheochromocytoma in an accessory adrenal gland 8 mm in diameter. The bean-shaped structure is the left semilunar celiac ganglion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32629=[""].join("\n");
var outline_f31_55_32629=null;
var title_f31_55_32630="Intensity-modulated radiation therapy";
var content_f31_55_32630=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intensity-modulated radiation therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/55/32630/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32630/contributors\">",
"     Igor J Barani, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32630/contributors\">",
"     Peck-Sun Lin, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32630/contributors\">",
"     Bruce P Libby, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32630/contributors\">",
"     Stanley H Benedict, Jr, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/55/32630/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32630/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/55/32630/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32630/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/55/32630/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful tumor treatment with external beam radiation therapy (EBRT) generally requires relatively high doses of radiation administered to the known areas of disease as well as to adjacent regions that potentially contain cancer cells. Incidental irradiation of adjacent normal structures is inevitable during such therapy. This radiation to normal tissues must be minimized to reduce both acute and long-term side effects.",
"   </p>",
"   <p>",
"    Advances in computer technology led to the development of sophisticated three-dimensional (3D) RT planning systems and computer-controlled RT delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Using these planning and delivery techniques, three-dimensional conformal radiation therapy (3D-CRT, conformal RT) became possible. 3D-CRT is typically implemented with a set of fixed radiation beams that radiate the tumor from different angles. The angles and shapes of the beams are chosen based upon the shape and size of the target.",
"   </p>",
"   <p>",
"    Intensity modulated RT (IMRT) requires the same careful 3D radiation treatment planning used for 3D-CRT. However, IMRT utilizes variable, computer-controlled intensities within each RT beam, in contrast to the uniform doses within each 3D-CRT beam. Compared to most other treatment techniques, IMRT can achieve a higher degree of accuracy in conformation of the radiation to the planned target, while sparing normal tissue. The advantages of IMRT are particularly evident when the target volumes have complex shapes, concave regions, or are adjacent to many critical normal structures.",
"   </p>",
"   <p>",
"    The concepts underlying IMRT and its application will be reviewed here. The application of IMRT to specific tumors is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23290?source=see_link&amp;anchor=H4#H4\">",
"     \"External beam radiation therapy for localized prostate cancer\", section on 'Intensity-modulated RT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     3D RT PLANNING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early RT planning systems depended upon two-dimensional contour information and calculated doses based upon relatively simple two-dimensional dose models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This type of planning was widely used until approximately 10 years ago when it was supplanted by 3D dose calculations, which integrate the detailed knowledge of the patient's anatomy, determined through the use of CT and MRI, with commercially available treatment planning systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/6-13\">",
"     6-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal of treatment planning is to calculate a plan in which the radiation dose conforms to the desired target volume and is homogeneous, such that there are no areas within the target that are undertreated or areas outside the treatment volume that receive excessive doses of radiation. In addition, varying the dose administered within each beam enables IMRT to simultaneously treat multiple areas within the target to different dose levels, thus providing a simultaneous integrated boost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/14\">",
"     14",
"    </a>",
"    ]. At the same time, tight conformity of dose distributions to target structures allows IMRT to better preserve surrounding normal structures from high-dose radiation, thereby limiting treatment-related toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IMRT treatment plans are usually generated using inverse planning and automated 3D treatment planning systems. The desired dose to the tumor is specified, along with the dose immediately adjacent to normal tissues. Computer optimization techniques then generate a treatment plan that meets these specifications, using multiple beams and varying the dose intensities within each beam.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TARGET VOLUME AND DOSE SPECIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parameters that define the target during treatment planning include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gross tumor volume (GTV) &mdash; The GTV is defined by imaging the tumor using contemporary modalities such as magnetic resonance imaging (MRI), computed tomography (CT) or positron emission tomography (PET). Increasingly, multiple imaging modalities are used to define the GTV and then the images are \"fused\" in the treatment planning system.",
"     </li>",
"     <li>",
"      Clinical target volume (CTV) &mdash; The CTV extends beyond the GTV and accounts for potential microscopic spread of the tumor outside the area defined by imaging. The delineation of CTV depends upon knowledge of the behavior of a specific tumor.",
"     </li>",
"     <li>",
"      Internal target volume (ITV) &mdash; The ITV accounts for the displacement of tumors particularly during respiratory motion.",
"     </li>",
"     <li>",
"      Planning treatment volume (PTV) &mdash; The PTV can extend beyond the CTV, to ensure appropriate treatment of the entire CTV. Variation in radiation delivery can be due to lack of reproducibility between treatment setup between fractions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      organ motion during therapy. These sources of variation can lead to underdosing of the CTV",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      overdosing of the surrounding normal structures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The conventional approach of creating a PTV by uniform geometric expansion of the CTV is not adequate for IMRT. Definition of PTV must be individualized and reevaluated upon review of the generated treatment plan to ensure adequate target organ coverage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Organ at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The organs at risk are those normal organs or tissues for which dose is constrained, so that the delivered dose is lower than the tissue tolerance. The OAR can either be the organ itself, or an expansion of the organ or tissue (such as the spinal cord), so that the critical part of the organ is protected from the delivery of higher doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IMRT DELIVERY TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The delivery of IMRT can utilize a number of variations that are superimposed upon conventional radiation techniques. In planning IMRT, each radiation field is subdivided, and the amount of radiation delivered to each of these subdivisions is varied. Precise control of the radiation intensity within each beam can be implemented in several ways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Multileaf collimator systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common approach to control the dose of radiation is the use of multileaf collimators (MLCs), which turn the beam on or off as treatment progresses.",
"   </p>",
"   <p>",
"    Specific techniques utilizing MLCs include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dynamic MLC IMRT &mdash; In dynamic MLC IMRT (DMLC), computer controlled MLCs are mounted on a linear accelerator. For each position of the gantry holding the linear accelerator, the aperture formed by each pair of opposing MLC leaves is swept across the target volume under computer control while the radiation beam is on, to produce the desired radiation intensity. This technique is often called \"sliding window\" IMRT.",
"     </li>",
"     <li>",
"      Static IMRT &mdash; With static IMRT, each field is divided into a series of multiple segments, in each of which a series of MLC shapes is delivered from the same gantry angle to achieve intensity modulation. The multiple segments are set up at each gantry position under computer control and the radiation is turned on only when the MLC leaves are in the prescribed position. This IMRT method is also called step-and-shoot, stop-and-shoot, or segmental MLC (SMLC).",
"     </li>",
"     <li>",
"      Dynamic conformal arc therapy (DCAT) &mdash; While IMRT is usually inverse planned, using computer algorithms to optimize the treatment, DCAT is forward planned. In forward planning, at each gantry angle of the arc the field aperture is manually adjusted so that the target is radiated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intensity-modulated arc therapy (IMAT) &mdash; Intensity-modulated arc therapy uses multiple irregular fields shaped with conventional MLCs during gantry rotation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/19\">",
"       19",
"      </a>",
"      ]. This form of therapy is planned as a series of static fields, every 5 to 10 degrees apart, but delivered with multiple superimposing arcs. Within each arc, the MLC shape is dynamically changed as a function of gantry angle such that the cumulative intensity distribution leads to the calculated dose distribution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Volumetric modulated arc therapy (VMAT) &mdash; VMAT treats a patient using one or more arcs, with the MLC defined aperture constantly changing, as well as the rotation speed and the dose rate (",
"      <a class=\"graphic graphic_figure graphicRef55906 \" href=\"mobipreview.htm?40/43/41650\">",
"       figure 1",
"      </a>",
"      ). VMAT differs from tomotherapy because it can treat the entire tumor volume at once, rather than slice by slice, and is delivered using a conventional linear accelerator [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/21\">",
"       21",
"      </a>",
"      ]. It is also more efficient than conventional IMRT, in that the treatment is delivered over all gantry angles, rather than at a number of specific angles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/22\">",
"       22",
"      </a>",
"      ]. The total integral dose (number of monitor units) is also reduced, which can reduce the possibility of second malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tomotherapy IMRT &mdash; Tomotherapy IMRT (or \"slice therapy\") uses a narrow slit beam in a manner analogous to a CT scanner (",
"      <a class=\"graphic graphic_figure graphicRef67526 \" href=\"mobipreview.htm?9/29/9680\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/24\">",
"       24",
"      </a>",
"      ]. An MLC system is attached to a conventional low-energy megavoltage linear accelerator, and treatment is delivered to a narrow slice of the patient using arc rotation. The beam intensity is varied by interposing the leaves of the collimator in and out of the radiation beam path as the gantry rotates around the patient. The complete treatment is accomplished by delivery to adjoining axial slices. Tomotherapy can be integrated with diagnostic CT systems, permitting real-time treatment monitoring and image-guidance (image-guided radiotherapy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other approaches not using MLCs have also been used to administer IMRT. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compensator-based IMRT &mdash; Complex filters can be designed to control the intensity of the radiation beams, based upon the 3D planning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]. This approach has some advantages over MLC-based methods, including higher resolution in the direction perpendicular to the leaf motion, higher precision, simpler quality assurance, and fewer problems matching adjacent fields. However, compensator-based IMRT necessitates a cumbersome and time-consuming manufacturing process for each patient. Furthermore, this approach requires that therapists enter the treatment room after each gantry rotation to change the filter, thereby prolonging patient's treatment time. Compensator-based IMRT is not widely used since most radiation therapy facilities prefer other forms of IMRT delivery.",
"     </li>",
"     <li>",
"      Robotic Linac IMRT &mdash; A small X-band linear accelerator mounted on an industrial robot arm was first used as a stereotactic radiosurgery device in the late 1990s [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/29\">",
"       29",
"      </a>",
"      ]&nbsp;(",
"      <a class=\"graphic graphic_figure graphicRef68913 \" href=\"mobipreview.htm?42/12/43201\">",
"       figure 3",
"      </a>",
"      ). Subsequently, the use of this device (commercially known as Cyberknife) for sophisticated IMRT was proposed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/30\">",
"       30",
"      </a>",
"      ]. In this approach, the robot arm provides the ability to aim small beamlets of radiation with any orientation relative to the target volume, thus giving this form of IMRT more flexibility than any of those previously discussed. The treatment plan is thus determined by the trajectory of the robot and the dose delivered at each orientation. This approach is still primarily reserved for stereotactic radiosurgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=see_link\">",
"       \"Stereotactic cranial radiosurgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=see_link\">",
"       \"Stereotactic body radiation therapy: Rationale and clinical experience\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment plans can demonstrate that IMRT administers higher doses of radiation to the PTV, while decreasing radiation to adjacent normal tissue. However, there are no randomized trials that demonstrate superior clinical outcomes for IMRT compared to 3D-CRT, nor are any randomized trials likely given the large numbers of patients, long duration of follow-up, and high costs that would be involved.",
"   </p>",
"   <p>",
"    The two clinical settings where there is the most experience with IMRT are in the treatment of prostate cancer and head and neck cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prostate cancer &mdash; An adequate dose of RT is an important component of therapy when external beam RT is used to treat prostate cancer. 3D-CRT has been a significant advance in facilitating the higher doses required for tumor control while minimizing toxicity to the bladder and rectum. IMRT may offer further advantages, especially for the treatment of pelvic lymph nodes. The results with IMRT in the treatment of prostatic cancer are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23290?source=see_link&amp;anchor=H4#H4\">",
"       \"External beam radiation therapy for localized prostate cancer\", section on 'Intensity-modulated RT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Head and neck cancer &mdash; In cancers of the head and neck, proximity to critical normal structures limits the dose that can be administered. An important goal of highly conformal RT planning and delivery is sparing of the parotid gland and less xerostomia. The potential role of IMRT in patients with head and neck cancer is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17525?source=see_link&amp;anchor=H1493365078#H1493365078\">",
"       \"General principles of radiation therapy for head and neck cancer\", section on 'Intensity-modulated RT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intensity modulated radiosurgery (IMRS) &mdash; For intracranial treatment of multiple brain metastases, IMRS can be used to treat all metastases with a single treatment, rather than treatment of each using separate plans with multiple isocenters [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=see_link\">",
"       \"Stereotactic cranial radiosurgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=see_link\">",
"       \"Stereotactic body radiation therapy: Rationale and clinical experience\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dosimetric verification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the advanced technologies used in all IMRT treatments, it is the standard practice to verify the delivered dose experimentally before the treatment is delivered to a patient. Originally, this was accomplished by delivering the treatment plan to a combination of film and an ionization chamber to confirm both the dose and the dose distributions. Due to the expense of film processors, different devices that do not require a processor have been developed to measure planar dose distributions, including arrays of ionization chambers (Matrixx, Scanditronix Wellhoffer, Inc) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], arrays of diodes (MapCheck, Sun Nuclear, Inc) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/34\">",
"     34",
"    </a>",
"    ], amorphous silicon (a-Si) portal imagers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/35\">",
"     35",
"    </a>",
"    ], or gafchromic(TM) film (EBT2, International Specialty Products) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=see_link\">",
"       \"Patient information: Radiation therapy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensity modulated radiation therapy (IMRT) is a technique that uses non-uniform radiation beam intensities to deliver a treatment plan that maximizes the homogenous delivery of radiation to the planned treatment volume, while minimizing irradiation to normal tissue outside the target. The combination of 3D planning plus variable radiation intensities for each field has allowed improvement in these parameters compared to conventional 3D conformal RT. (See",
"    <a class=\"local\" href=\"#H2\">",
"     '3D RT planning'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'IMRT delivery techniques'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus IMRT may permit the administration of higher doses that result in better tumor control or result in decreased toxicity. One theoretical disadvantage of IMRT is the prolonged treatment time compared to other treatment techniques, with its unknown biological impact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. In addition, IMRT results in a larger volume of normal tissue receiving low-doses of irradiation as a consequence of an increased number of incident and exit beams [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32630/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. These drawbacks may be particularly important in children and other patients with a prolonged anticipated survival, where heterogeneous low-dose volume may result in a higher incidence of secondary malignancies or unintended developmental consequences.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/1\">",
"      Mackie TR. Radiation therapy treatment optimization. Introduction. Semin Radiat Oncol 1999; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/2\">",
"      Purdy JA. Advances in three-dimensional treatment planning and conformal dose delivery. Semin Oncol 1997; 24:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/3\">",
"      Purdy JA. 3D treatment planning and intensity-modulated radiation therapy. Oncology (Williston Park) 1999; 13:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/4\">",
"      Shepard DM, Olivera GH, Reckwerdt PJ, Mackie TR. Iterative approaches to dose optimization in tomotherapy. Phys Med Biol 2000; 45:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/5\">",
"      Bentley RE, Milan J. An interactive digital computer system for radiotherapy treatment planning. Br J Radiol 1971; 44:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/6\">",
"      Holmes WF. External beam treatment-planning with the programmed console. Radiology 1970; 94:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/7\">",
"      Sterling TD, Knowlton KC, Weinkam JJ, Sterling DM. Dynamic display of radiotherapy plans using computer-produced films. Radiology 1973; 107:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/8\">",
"      Sterling TD, Perry H, Weinkam JJ. Automation of radiation treatment planning. V. Calculation and visualisation of the total treatment volume. Br J Radiol 1965; 38:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/9\">",
"      van de Geijn J. EXTDOS 71. Revised and expanded version of EXTDOS, a program for treatment planning in external beam therapy. Comput Programs Biomed 1972; 2:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/10\">",
"      VAN DE GEIJN J. THE COMPUTATION OF TWO AND THREE DIMENSIONAL DOSE DISTRIBUTIONS IN COBALT 60 TELETHERAPY. Br J Radiol 1965; 38:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/11\">",
"      Cunningham JR. Scatter-air ratios. Phys Med Biol 1972; 17:42.",
"     </a>",
"    </li>",
"    <li>",
"     Beaudoin, L. Analytical approach to the solution of dosimetry in heterogeneous media [Ph.D. Thesis] 1968.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/13\">",
"      Sontag MR, Cunningham JR. The equivalent tissue-air ratio method for making absorbed dose calculations in a heterogeneous medium. Radiology 1978; 129:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/14\">",
"      Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 2000; 46:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/15\">",
"      Garden AS, Morrison WH, Wong PF, et al. Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007; 67:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/16\">",
"      Guerrero Urbano MT, Nutting CM. Clinical use of intensity-modulated radiotherapy: part I. Br J Radiol 2004; 77:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/17\">",
"      Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006; 66:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/18\">",
"      Ding, M, Newman, F, Kavanaugh, BD, et al. Comparative Dosimetric Study of Three Dimensional Conformal, Dynamic Conformal Arc, and Intensity Modulated Radiotherapy for Brain Tumor Treatment Using Novalis System. Int J Radiat Oncol Biol Phys 2006; 66:S82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/19\">",
"      Wong E, D'Souza DP, Chen JZ, et al. Intensity-modulated arc therapy for treatment of high-risk endometrial malignancies. Int J Radiat Oncol Biol Phys 2005; 61:830.",
"     </a>",
"    </li>",
"    <li>",
"     Yu, CX, Chen, DJ, Li, A. Intensity-modulated arc therapy: clinical implementation and experience. Proceedings of the 13th International Conference on the Use of Computers in Radiotherapy, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/21\">",
"      Palma DA, Verbakel WF, Otto K, Senan S. New developments in arc radiation therapy: a review. Cancer Treat Rev 2010; 36:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/22\">",
"      Bedford JL, Warrington AP. Commissioning of volumetric modulated arc therapy (VMAT). Int J Radiat Oncol Biol Phys 2009; 73:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/23\">",
"      Matuszak MM, Yan D, Grills I, Martinez A. Clinical applications of volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 2010; 77:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/24\">",
"      Mackie TR, Holmes T, Swerdloff S, et al. Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys 1993; 20:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/25\">",
"      Lu W, Olivera GH, Chen Q, et al. Automatic re-contouring in 4D radiotherapy. Phys Med Biol 2006; 51:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/26\">",
"      Gustafsson A, Lind BK, Svensson R, Brahme A. Simultaneous optimization of dynamic multileaf collimation and scanning patterns or compensation filters using a generalized pencil beam algorithm. Med Phys 1995; 22:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/27\">",
"      Jiang SB, Ayyangar KM. On compensator design for photon beam intensity-modulated conformal therapy. Med Phys 1998; 25:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/28\">",
"      Mageras GS, Mohan R, Burman C, et al. Compensators for three-dimensional treatment planning. Med Phys 1991; 18:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/29\">",
"      Schweikard A, Adler JR. Robotic radiosurgery with noncylindrical collimators. Comput Aided Surg 1997; 2:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/30\">",
"      Webb S. Conformal intensity-modulated radiotherapy (IMRT) delivered by robotic linac--conformality versus efficiency of dose delivery. Phys Med Biol 2000; 45:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/31\">",
"      Lawson JD, Wang JZ, Nath SK, et al. Intracranial application of IMRT based radiosurgery to treat multiple or large irregular lesions and verification of infra-red frameless localization system. J Neurooncol 2010; 97:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/32\">",
"      Alashrah, S, Kandaiya, S, Yong, SY, Cheng, SK. Characterization of a 2D ionization chamber array for IMRT plan validation. Nucl Instr Meth A 2010; :.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/33\">",
"      Bhardwaj, AK, Sharma, SC, Rana, B, Shukla, A. Study of 2D ion chamber array for angular response and QA of dynamic MLC and pretreatment IMRT plans. Rep Pract Oncol Radiother 2009; 14:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/34\">",
"      L&eacute;tourneau D, Gulam M, Yan D, et al. Evaluation of a 2D diode array for IMRT quality assurance. Radiother Oncol 2004; 70:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/35\">",
"      Mans A, Remeijer P, Olaciregui-Ruiz I, et al. 3D Dosimetric verification of volumetric-modulated arc therapy by portal dosimetry. Radiother Oncol 2010; 94:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/36\">",
"      Schneider F, Polednik M, Wolff D, et al. Optimization of the gafchromic EBT protocol for IMRT QA. Z Med Phys 2009; 19:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/37\">",
"      Kry SF, Salehpour M, Followill DS, et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005; 62:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/38\">",
"      Paganetti H. Changes in tumor cell response due to prolonged dose delivery times in fractionated radiation therapy. Int J Radiat Oncol Biol Phys 2005; 63:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/39\">",
"      Sch&auml;fer M, M&uuml;nter M, Sterzing F, et al. Measurements of characteristics of time pattern in dose delivery in step-and-shoot IMRT. Strahlenther Onkol 2005; 181:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/40\">",
"      Sterzing F, M&uuml;nter MW, Sch&auml;fer M, et al. Radiobiological investigation of dose-rate effects in intensity-modulated radiation therapy. Strahlenther Onkol 2005; 181:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/41\">",
"      Zheng XK, Chen LH, Yan X, Wang HM. Impact of prolonged fraction dose-delivery time modeling intensity-modulated radiation therapy on hepatocellular carcinoma cell killing. World J Gastroenterol 2005; 11:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/42\">",
"      Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32630/abstract/43\">",
"      Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003; 56:83.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7064 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32630=[""].join("\n");
var outline_f31_55_32630=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      3D RT PLANNING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TARGET VOLUME AND DOSE SPECIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Organ at risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IMRT DELIVERY TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Multileaf collimator systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dosimetric verification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7064\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7064|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/43/41650\" title=\"figure 1\">",
"      Volumetric modulated arc therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/29/9680\" title=\"figure 2\">",
"      Cyberknife system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/12/43201\" title=\"figure 3\">",
"      Tomotherapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23290?source=related_link\">",
"      External beam radiation therapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_55_32631="Saw palmetto";
var content_f31_55_32631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saw palmetto",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 491px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Martin Wall/herbslides.com.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32631=[""].join("\n");
var outline_f31_55_32631=null;
var title_f31_55_32632="Clinical manifestations and diagnosis of rhabdomyolysis";
var content_f31_55_32632=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of rhabdomyolysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/55/32632/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32632/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/55/32632/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32632/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32632/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/55/32632/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32632/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/55/32632/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H31738287\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis is a syndrome characterized by muscle necrosis and the release of intracellular muscle constituents into the circulation. Creatine kinase levels are typically markedly elevated, and muscle pain and myoglobinuria may be present. The severity of illness ranges from asymptomatic elevations in serum muscle enzymes to life-threatening disease associated with extreme enzyme elevations, electrolyte imbalances, and acute kidney injury.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of rhabdomyolysis will be reviewed here. The causes of rhabdomyolysis; the clinical features and diagnosis of acute kidney injury due to rhabdomyolysis; the management of patients with rhabdomyolysis, including methods to prevent acute kidney injury and related metabolic complications; and the prevention and management of acute compartment syndrome are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15369?source=see_link\">",
"     \"Crush-related acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25330957\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis is characterized clinically by myalgias, red to brown urine due to myoglobinuria, and elevated serum muscle enzymes (including creatine kinase) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/1\">",
"     1",
"    </a>",
"    ]. The degree of muscle pain and other symptoms varies widely. Rhabdomyolysis associated with viral infection is discussed in further detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9879?source=see_link&amp;anchor=H4#H4\">",
"     \"Viral myositis\", section on 'Viral myositis with rhabdomyolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25330880\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic triad of complaints in rhabdomyolysis is muscle pain, weakness, and dark urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. However, more than half of patients may not report muscular symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/3\">",
"     3",
"    </a>",
"    ]; in contrast, occasional others may experience very severe pain. Muscle pain, when present, is typically most prominent in proximal muscle groups, such as the thighs and shoulders, and in the lower back and calves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Other muscle symptoms include stiffness and cramping.",
"   </p>",
"   <p>",
"    Additional symptoms that are more common in severely affected patients include malaise, fever, tachycardia, nausea and vomiting, and abdominal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/2\">",
"     2",
"    </a>",
"    ]. Altered mental status may occur from the underlying etiology (eg, toxins, drugs, trauma, or electrolyte abnormalities).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25330888\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle tenderness and swelling may be seen, but detectable muscle swelling in the extremities generally develops, when it occurs, with fluid repletion. Such swelling is much less common on hospital admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/3\">",
"     3",
"    </a>",
"    ]. Muscle weakness may be present, depending upon the severity of muscle injury. Limb induration is occasionally present. Skin changes of ischemic tissue injury, such as discoloration or blisters, may also be seen but are present in less than 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25330896\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of rhabdomyolysis is an elevation in creatine kinase and other serum muscle enzymes. The other characteristic finding is the reddish-brown urine of myoglobinuria, but because this may be observed in only half of cases, its absence does not exclude the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25326274\">",
"    <span class=\"h3\">",
"     Creatine kinase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum creatine kinase (CK) levels at presentation are usually at least five times the upper limit of normal, but range from approximately 1500 to over 100,000 international",
"    <span class=\"nowrap\">",
"     units/L.",
"    </span>",
"    The mean peak CK reported for each of a variety of different causes and for patients with both single and multiple causes ranged from approximately 10,000 to 25,000 in the largest series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/7\">",
"     7",
"    </a>",
"    ]; exceptions were the three patients with malignant hyperthermia, whose values averaged almost 60,000.",
"   </p>",
"   <p>",
"    The CK is generally entirely or almost entirely of the MM or skeletal muscle fraction; a small proportion of the total CK may be from the MB or myocardial fraction. The presence of MB reflects the small amount found in skeletal muscle rather than the presence of myocardial disease. Elevations in serum aminotransferases are common and can cause confusion if attributed to liver disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36745?source=see_link\">",
"     \"Muscle enzymes in the evaluation of neuromuscular diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum CK begins to rise within 2 to 12 hours following the onset of muscle injury and reaches its maximum within 24 to 72 hours. A decline is usually seen within three to five days of cessation of muscle injury. CK has a serum half-life of about 1.5 days and declines at a relatively constant rate of about 40 to 50 percent of the previous day&rsquo;s value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/5,6,8\">",
"     5,6,8",
"    </a>",
"    ]. In patients whose CK does not decline as expected, continued muscle injury or the development of a compartment syndrome may be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25326281\">",
"    <span class=\"h3\">",
"     Urine findings and myoglobinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoglobin, a heme-containing respiratory protein, is released from damaged muscle in parallel with CK. Myoglobin is a monomer that is not significantly protein bound and is, therefore, rapidly excreted in the urine, often resulting in the production of red to brown urine. It appears in the urine when the plasma concentration exceeds 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/5\">",
"     5",
"    </a>",
"    ]. Visible changes in the urine only occur once urine levels exceed from about 100 to 300",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    although it can be detected by the urine (orthotolidine) dipstick at concentrations of only 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Myoglobin has a half-life of only two to three hours, much shorter than that of CK. Because of its rapid excretion and metabolism to bilirubin, serum levels may return to normal within six to eight hours.",
"   </p>",
"   <p>",
"    Thus, it is not unusual for CK levels to remain elevated in the absence of myoglobinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/3\">",
"     3",
"    </a>",
"    ]. Routine urine testing for myoglobin by urine dipstick evaluation may be negative in up to half of patients with rhabdomyolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/2\">",
"     2",
"    </a>",
"    ]. Pigmenturia will be missed in rhabdomyolysis if the filtered load of myoglobin is insufficient or has largely resolved before the patient seeks medical attention due to its rapid clearance.",
"   </p>",
"   <p>",
"    Both hemoglobin and myoglobin can be detected on the urine dipstick as &ldquo;blood&rdquo;; microscopic evaluation of the urine generally shows few red blood cells (less than five per high-powered field) in patients with rhabdomyolysis whose positive test results from myoglobinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/2\">",
"     2",
"    </a>",
"    ]. Such testing is not a reliable method for rapid detection of myoglobin if red blood cells are present or in patients with hemolysis due to its lack of specificity for myoglobin. Hemoglobin, the other heme pigment capable of producing pigmented urine, is much larger (a tetramer) than myoglobin and is protein bound. As a result, much higher plasma concentrations are required before red to brown urine is seen, resulting in a change in plasma color. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H1824471583#H1824471583\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Red to brown urine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proteinuria may also be seen, due to the release of myoglobin and other proteins by the damaged myocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/2\">",
"     2",
"    </a>",
"    ]. In one study, it was detected by dipstick in 45 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25330918\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other manifestations of rhabdomyolysis include fluid and electrolyte abnormalities, many of which precede or occur in the absence of kidney failure, and hepatic injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/9\">",
"     9",
"    </a>",
"    ]; additionally, cardiac dysrhythmias and risk of cardiac arrest may result from the severe hyperkalemia that occurs with significant myonecrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/5\">",
"     5",
"    </a>",
"    ]. Later complications include acute kidney injury, compartment syndrome, and, rarely, disseminated intravascular coagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25326295\">",
"    <span class=\"h3\">",
"     Fluid and electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypovolemia and abnormalities in serum electrolytes and uric acid are common in patients with rhabdomyolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/3,10,11\">",
"     3,10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypovolemia results from &ldquo;third-spacing&rdquo; due to the influx of extracellular fluid into injured muscles and increases the risk of acute kidney injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperkalemia and hyperphosphatemia result from the release of potassium and phosphorus from damaged muscle cells. Levels of potassium may increase rapidly, but the levels of potassium and phosphate decrease as they are excreted in the urine. Hyperkalemia is more common in patients with oliguric acute kidney injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypocalcemia, which can be extreme, occurs in the first few days because of entry into damaged myocytes and both deposition of calcium salts in damaged muscle and decreased bone responsiveness to parathyroid hormone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. During the recovery phase, serum calcium levels return to normal and may rebound to significantly elevated levels due to the release of calcium from injured muscle, mild secondary hyperparathyroidism from the acute renal failure, and an increase in calcitriol (1,25-dihydroxyvitamin D) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24984?source=see_link&amp;anchor=H16#H16\">",
"       \"Etiology of hypocalcemia in adults\", section on 'Extravascular deposition'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28007?source=see_link&amp;anchor=H18#H18\">",
"       \"Etiology of hypercalcemia\", section on 'Rhabdomyolysis and acute renal failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe hyperuricemia may develop because of the release of purines from damaged muscle cells and, if acute kidney injury occurs, reduced urinary excretion.",
"     </li>",
"     <li>",
"      Metabolic acidosis is common, and an increased anion gap may be present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25331868\">",
"    <span class=\"h3\">",
"     Acute kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI, acute renal failure) is a common complication of rhabdomyolysis. The reported frequency of AKI ranges from 15 to over 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/3,7,15\">",
"     3,7,15",
"    </a>",
"    ]. The risk of AKI is lower in patients with CK levels at admission less than 15 to 20,000",
"    <span class=\"nowrap\">",
"     units/L;",
"    </span>",
"    risk factors for AKI in patients with lower values include dehydration, sepsis, and acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/12\">",
"     12",
"    </a>",
"    ]. Volume depletion resulting in renal ischemia, tubular obstruction due to heme pigment casts, and tubular injury from free chelatable iron all contribute to the development of renal dysfunction. Reddish-gold pigmented casts are often observed in the urine sediment. AKI in patients with rhabdomyolysis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25326302\">",
"    <span class=\"h3\">",
"     Compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A compartment syndrome exists when increased pressure in a closed anatomic space threatens the viability of the muscles and nerves within the compartment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/16\">",
"     16",
"    </a>",
"    ]. Compartment syndrome is a potential complication of severe rhabdomyolysis that may develop after fluid resuscitation, with worsening edema of the limb and muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/17\">",
"     17",
"    </a>",
"    ]. Lower extremity compartment syndrome can also be a cause of rhabdomyolysis, as may occur after tibial fractures. Compartment syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300169955\">",
"    <span class=\"h3\">",
"     Disseminated intravascular coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequently, severe rhabdomyolysis may be associated with the development of disseminated intravascular coagulation due to the release of thromboplastin and other prothrombotic substances from the damaged muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/5,18,19\">",
"     5,18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8073?source=see_link\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25326606\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86659023\">",
"    <span class=\"h2\">",
"     Indications for diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic testing should be performed in individuals with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both myalgias and pigmenturia",
"     </li>",
"     <li>",
"      Either myalgias or pigmenturia, with a history suggesting the presence or recent exposure to a potential cause or event (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/33/10777?source=see_link&amp;anchor=H31734787#H31734787\">",
"       \"Causes of rhabdomyolysis\", section on 'Causes'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The absence of myalgias or pigmenturia in a clinical setting associated with increased risk for rhabdomyolysis, as symptoms may be vague or absent in up to 50 percent of patients. The diagnosis should be suspected following prolonged immobilization, in any stuporous or comatose patient or in a patient who is otherwise unable to provide a medical history and has one or more of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Muscle tenderness",
"     </li>",
"     <li>",
"      Evidence of pressure necrosis of the skin",
"     </li>",
"     <li>",
"      Signs of multiple trauma or a crush injury",
"     </li>",
"     <li>",
"      Blood chemistry abnormalities suggesting the possibility of increased cell breakdown, such as hyperkalemia, hyperphosphatemia, and",
"      <span class=\"nowrap\">",
"       /or",
"      </span>",
"      hypocalcemia",
"     </li>",
"     <li>",
"      Evidence of acute kidney injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86659030\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We obtain the following key diagnostic laboratory studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Creatine kinase &mdash; Fractionation of the CK is generally not required but may be helpful, in addition to the clinical history and examination, in excluding other potential causes of CK elevation such as acute myocardial infarction, stroke, and other diseases of the heart and brain. (See",
"      <a class=\"local\" href=\"#H25326274\">",
"       'Creatine kinase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinalysis, including dipstick and microscopic evaluation &mdash; Evidence of myoglobinuria should be sought by routine urine dipstick evaluation combined with microscopic examination. Testing of the unspun urine or the supernatant of the centrifuged urine will be positive for &ldquo;heme&rdquo; on dipstick if myoglobinuria is present, even if red to reddish brown urine is not evident macroscopically. The visual and microscopic examination of the sediment from a fresh urine specimen is required to exclude the presence of red blood cells (RBC) as the cause of positive testing; RBC in an older specimen may hemolyze over time, confounding the results. (See",
"      <a class=\"local\" href=\"#H25326281\">",
"       'Urine findings and myoglobinuria'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In patients with persistent red to reddish-brown urine, myoglobinuria is suggested when the urine tests positive for heme by dipstick after centrifugation, while the plasma has a normal color and tests negative for heme (",
"      <a class=\"graphic graphic_algorithm graphicRef55923 \" href=\"mobipreview.htm?22/63/23550\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H1824471583#H1824471583\">",
"       \"Etiology and evaluation of hematuria in adults\", section on 'Red to brown urine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Myoglobinuria lacks sensitivity as a test for rhabdomyolysis; it may be absent in 25 to 50 percent of patients with rhabdomyolysis due to the more rapid clearance of myoglobin, compared with CK, following muscle injury. Myoglobin also decreases rapidly in a similar fashion in patients with renal failure, suggesting a role for extrarenal metabolism and clearance in such patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We also obtain the following tests, which may help in prompt recognition of other potentially dangerous manifestations, in differential diagnosis, and in identifying the cause (see",
"    <a class=\"local\" href=\"#H25619306\">",
"     'Management'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count, including differential and platelet count",
"     </li>",
"     <li>",
"      Blood urea nitrogen, creatinine, and routine electrolytes including potassium",
"     </li>",
"     <li>",
"      Calcium, phosphate, albumin, and uric acid",
"     </li>",
"     <li>",
"      Electrocardiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional testing, such as evaluation of suspected metabolic myopathy or toxicology screening for drugs of abuse, depends upon the clinical context. (See",
"    <a class=\"local\" href=\"#H244425159\">",
"     'When to suspect metabolic myopathy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244425251\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We make the diagnosis of rhabdomyolysis in a patient with either an acute neuromuscular illness or dark urine without other symptoms, plus a marked acute elevation in serum creatine kinase (CK). The CK is typically at least five times the upper limit of normal, and is usually greater than 5000 international",
"    <span class=\"nowrap\">",
"     units/L.",
"    </span>",
"    No absolute cut-off value for CK elevation can be defined, and the CK should be considered in the clinical context of the history and examination findings. (See",
"    <a class=\"local\" href=\"#H25326274\">",
"     'Creatine kinase'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following additional points should be considered in making the diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other muscle enzymes in addition to CK are typically elevated (eg, aldolase, aminotransferases, lactate dehydrogenase), but such testing is not usually necessary to make the diagnosis. However, elevations in aminotransferases or lactate dehydrogenase may suggest the need for CK testing if it has not been performed in a patient in whom such abnormalities may potentially be due to muscle injury rather than hepatic injury or another cause.",
"     </li>",
"     <li>",
"      In patients with dark urine, but without elevation in the CK, additional diagnostic considerations should be explored. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H1824471583#H1824471583\">",
"       \"Etiology and evaluation of hematuria in adults\", section on 'Red to brown urine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A muscle biopsy is generally not required. Findings on biopsy include loss of normal cross-striations and cell nuclei and the absence of inflammatory cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Electromyography (EMG) is generally not required. Findings are most often normal and are only mild when present. In one study of 15 patients with acute rhabdomyolysis, EMG testing was normal in three-quarters of the tested muscles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/23\">",
"       23",
"      </a>",
"      ]. One-third of patients had myopathic changes in one to several muscles (eg, proximal myopathic motor unit action potentials), and none exhibited persistent fibrillation potentials. Nerve conduction studies were normal, except for one patient with a preexisting polyneuropathy.",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) is generally not required. Findings in affected muscle include increased signal intensity on T2-weighted images and good contrast between normal and abnormal muscles on STIR images [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/24\">",
"       24",
"      </a>",
"      ]. MRI appears to be more sensitive than either ultrasound or computerized tomography in detecting abnormal muscle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rhabdomyolysis associated with viral infection is discussed in further detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9879?source=see_link&amp;anchor=H7#H7\">",
"     \"Viral myositis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244425159\">",
"    <span class=\"h2\">",
"     When to suspect metabolic myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are subtle differences in the clinical manifestations of the various metabolic myopathies, but one of these conditions should be suspected when the following clinical circumstances are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are recurrent episodes of rhabdomyolysis after exertion or in association with fasting or a viral illness. The last two associations occur most commonly with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      palmitoyltransferase deficiency and the other disorders of lipid metabolism.",
"     </li>",
"     <li>",
"      There is a history of exercise intolerance, recurrent cramps, and fatigue beginning in childhood, and episodes of pigmenturia occurring in adolescence.",
"     </li>",
"     <li>",
"      There is a family history of rhabdomyolysis or exercise intolerance, particularly in siblings, thereby suggestive of an autosomal recessive inheritance pattern.",
"     </li>",
"     <li>",
"      The individual has normal strength and muscle enzymes during interictal periods. One exception is muscle phosphorylase deficiency, a disorder in which chronic muscle weakness may develop after repeated episodes and CK levels do not return to normal between attacks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23928?source=see_link\">",
"       \"Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic approach to a suspected metabolic myopathy is discussed separately. Histochemical analysis of a muscle biopsy specimen will demonstrate the deficient enzyme. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/905?source=see_link&amp;anchor=H400795568#H400795568\">",
"     \"Approach to the metabolic myopathies\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26694?source=see_link\">",
"     \"Approach to the patient with muscle weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25326714\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnoses of myalgia, elevated CK and other muscle enzymes, and dark urine are fairly extensive. However, when present together, and if the CK elevation is acute and myoglobinuria is present, the diagnosis of rhabdomyolysis can generally be made with confidence. The following conditions may be considered, depending upon the combination of findings that are present, but distinctions can usually be made with readily available information from the medical history as well as the physical and laboratory examinations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myocardial infarction &mdash;Although serum CK also rises acutely with myocardial infarction, patients with rhabdomyolysis alone do not have ischemic chest pain or ECG signs of myocardial infarction. Additionally, the CK-MM fraction is elevated, while little or no CK-MB is present. Assays for cardiac troponin I appear to have high specificity for cardiac muscle injury, while assays for cardiac troponin T may exhibit cross-reactions with skeletal muscle troponin. Further study in patients with rhabdomyolysis is needed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link\">",
"       \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link&amp;anchor=H3#H3\">",
"       \"Troponins and creatine kinase as biomarkers of cardiac injury\", section on 'Troponins'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H25326274\">",
"       'Creatine kinase'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hematuria and hemoglobinuria &mdash; Both hematuria and hemoglobinuria (due to hemolysis) may result in red to reddish-brown urine and may be confused with myoglobinuria. Careful examination of the urine for red blood cells (present in hematuria, by definition), of serum for evidence of hemolysis, and of the CK (which is not elevated in hemolysis, or most patients with hematuria) will help distinguish these conditions. Other causes of red to brown urine include various foods and drugs, but such patients lack evidence of skeletal muscle injury, including CK elevation. (See",
"      <a class=\"local\" href=\"#H25326281\">",
"       'Urine findings and myoglobinuria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25326606\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H1824471583#H1824471583\">",
"       \"Etiology and evaluation of hematuria in adults\", section on 'Red to brown urine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory myopathy &mdash; Patients with inflammatory myopathy can also exhibit myalgias and elevated CK and may exhibit myoglobinuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/27\">",
"       27",
"      </a>",
"      ]. These patients can be differentiated from patients with rhabdomyolysis by the chronicity of disease, usually symmetric proximal muscle weakness developing over weeks to months, relative stability of the laboratory abnormalities compared with patients with rhabdomyolysis, and the systemic features associated with the inflammatory myopathies, such as dermatomyositis.",
"      <br/>",
"      <br/>",
"      Patients with rhabdomyolysis generally do not exhibit electromyographic or histologic changes suggestive of myositis except in rare patients in whom both are present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]; concurrent statin therapy may be a risk factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H25326606\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immune-mediated necrotizing myopathy &mdash; Patients on statin medications may develop an immune-mediated necrotizing myopathy with markedly elevated levels of CK and weakness that does not improve with discontinuation of statins but that does respond to aggressive immunosuppressive therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32632/abstract/32-35\">",
"       32-35",
"      </a>",
"      ]. These patients can be distinguished from patients with rhabdomyolysis by the persistence of symptoms and findings, including the elevation in CK, in the absence of treatment with immunosuppressives and by their histopathologic changes.",
"     </li>",
"     <li>",
"      Deep vein thrombosis &mdash; In patients who present with severe calf pain, a deep vein thrombosis (DVT) may be an initial consideration. DVT can be diagnosed in most patients by appropriate noninvasive studies and is not associated with marked CK elevations or myoglobinuria. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33994?source=see_link\">",
"       \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal colic &mdash; In patients presenting with back pain, rhabdomyolysis may be confused with renal colic. Additionally, urine dipstick testing may be positive for blood. However, urolithiasis is not associated with marked elevations of the CK, and myoglobinuria is not present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=see_link\">",
"       \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25619306\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major issues in the treatment of patients with rhabdomyolysis, which are discussed in detail separately, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recognition and management of fluid and electrolyte abnormalities, which should be initiated regardless of renal function and which may prevent severe metabolic disturbances and acute kidney injury (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22632?source=see_link\">",
"       \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Identification of the specific causes and the use of appropriate countermeasures directed at the triggering events, including discontinuation of drugs or other toxins that may be etiologic factors (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/33/10777?source=see_link&amp;anchor=H31734787#H31734787\">",
"       \"Causes of rhabdomyolysis\", section on 'Causes'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prompt recognition, evaluation, and treatment of compartment syndrome in patients in whom it is present (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15369?source=see_link\">",
"       \"Crush-related acute kidney injury (acute renal failure)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=see_link\">",
"       \"Acute compartment syndrome of the extremities\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/59/22450?source=see_link\">",
"       \"Patient information: Rhabdomyolysis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of rhabdomyolysis include myalgias, weakness, red to brown urine due to myoglobinuria, and elevated serum muscle enzymes (including creatine kinase). The degree of myalgias and other symptoms varies widely, and some patients are asymptomatic. Fever, malaise, tachycardia, and gastrointestinal symptoms may be present. Muscle swelling may occur with rehydration. (See",
"      <a class=\"local\" href=\"#H25330957\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25330880\">",
"       'Symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25330888\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laboratory findings that characterize rhabdomyolysis include an acute elevation in the creatine kinase and other muscle enzymes and a decline in these values within three to five days of cessation of muscle injury. The other characteristic finding is the reddish-brown urine of myoglobinuria, but this finding is often absent because of the relative rapidity with which myoglobin is cleared. The serum CK is generally entirely or almost entirely of the MM or skeletal muscle fraction, although small amounts of the MB fraction may be present. (See",
"      <a class=\"local\" href=\"#H25330896\">",
"       'Laboratory findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25326274\">",
"       'Creatine kinase'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25326281\">",
"       'Urine findings and myoglobinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other manifestations include fluid and electrolyte abnormalities, many of which precede or occur in the absence of acute kidney injury, and hepatic injury. Hypovolemia, hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia, and metabolic acidoses may be seen. Hyperkalemia may result in cardiac dysrhythmias. Later complications include acute kidney injury, hypercalcemia, compartment syndrome, and, rarely, disseminated intravascular coagulation. (See",
"      <a class=\"local\" href=\"#H25330918\">",
"       'Other manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25326295\">",
"       'Fluid and electrolyte abnormalities'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25331868\">",
"       'Acute kidney injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25326302\">",
"       'Compartment syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H300169955\">",
"       'Disseminated intravascular coagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We diagnose rhabdomyolysis in a patient with an acute muscular illness or injury based upon a marked acute elevation in serum creatine kinase (CK); the CK is typically at least five times the upper limit of normal and is frequently greater than 5000 international",
"      <span class=\"nowrap\">",
"       units/L.",
"      </span>",
"      Key diagnostic laboratory studies include the creatine kinase and urinalysis, including dipstick and microscopic evaluation. Myoglobinuria (present in 50 to 75 percent of patients at the time of initial evaluation) results in a positive test for blood on the urine dipstick but without red blood cells on the microscopic examination of the urine. (See",
"      <a class=\"local\" href=\"#H25326606\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis depends upon the combination of findings present. It includes myocardial infarction, other causes of red or brown urine, inflammatory myopathy, and local causes of pain, such as deep vein thrombosis or renal colic. (See",
"      <a class=\"local\" href=\"#H25326714\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/1\">",
"      Knochel JP. Rhabdomyolysis and myoglobinuria. Annu Rev Med 1982; 33:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/2\">",
"      Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. Eur J Intern Med 2007; 18:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/3\">",
"      Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore) 1982; 61:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/4\">",
"      Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: a review. Muscle Nerve 2002; 25:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/5\">",
"      Huerta-Alard&iacute;n AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians. Crit Care 2005; 9:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/6\">",
"      Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med 2009; 67:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/7\">",
"      Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/8\">",
"      Mikkelsen TS, Toft P. Prognostic value, kinetics and effect of CVVHDF on serum of the myoglobin and creatine kinase in critically ill patients with rhabdomyolysis. Acta Anaesthesiol Scand 2005; 49:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/9\">",
"      Akmal M, Massry SG. Reversible hepatic dysfunction associated with rhabdomyolysis. Am J Nephrol 1990; 10:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/10\">",
"      Grossman RA, Hamilton RW, Morse BM, et al. Nontraumatic rhabdomyolysis and acute renal failure. N Engl J Med 1974; 291:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/11\">",
"      Koffler A, Friedler RM, Massry SG. Acute renal failure due to nontraumatic rhabdomyolysis. Ann Intern Med 1976; 85:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/12\">",
"      Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/13\">",
"      Llach F, Felsenfeld AJ, Haussler MR. The pathophysiology of altered calcium metabolism in rhabdomyolysis-induced acute renal failure. Interactions of parathyroid hormone, 25-hydroxycholecalciferol, and 1,25-dihydroxycholecalciferol. N Engl J Med 1981; 305:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/14\">",
"      Akmal M, Bishop JE, Telfer N, et al. Hypocalcemia and hypercalcemia in patients with rhabdomyolysis with and without acute renal failure. J Clin Endocrinol Metab 1986; 63:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/15\">",
"      Veenstra J, Smit WM, Krediet RT, Arisz L. Relationship between elevated creatine phosphokinase and the clinical spectrum of rhabdomyolysis. Nephrol Dial Transplant 1994; 9:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/16\">",
"      Olson SA, Glasgow RR. Acute compartment syndrome in lower extremity musculoskeletal trauma. J Am Acad Orthop Surg 2005; 13:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/17\">",
"      Paletta CE, Lynch R, Knutsen AP. Rhabdomyolysis and lower extremity compartment syndrome due to influenza B virus. Ann Plast Surg 1993; 30:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/18\">",
"      Criddle LM. Rhabdomyolysis. Pathophysiology, recognition, and management. Crit Care Nurse 2003; 23:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/19\">",
"      Chatzizisis YS, Misirli G, Hatzitolios AI, Giannoglou GD. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med 2008; 19:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/20\">",
"      Wakabayashi Y, Kikuno T, Ohwada T, Kikawada R. Rapid fall in blood myoglobin in massive rhabdomyolysis and acute renal failure. Intensive Care Med 1994; 20:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/21\">",
"      Wakabayashi Y, Nakano T, Kikuno T, et al. Massive rhabdomyolysis associated with influenza A infection. Intern Med 1994; 33:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/22\">",
"      Hino I, Akama H, Furuya T, et al. Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease. Arthritis Rheum 1996; 39:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/23\">",
"      Al-Shekhlee A, Hachwi R, Jaberi MM, Katirji B. The electromyographic features of acute rhabdomyolysis. J Clin Neuromuscul Dis 2005; 6:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/24\">",
"      Moratalla MB, Braun P, Fornas GM. Importance of MRI in the diagnosis and treatment of rhabdomyolysis. Eur J Radiol 2008; 65:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/25\">",
"      Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006; 92:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/26\">",
"      Jaffe AS, Vasile VC, Milone M, et al. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol 2011; 58:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/27\">",
"      Rider LG, Miller FW. Laboratory evaluation of the inflammatory myopathies. Clin Diagn Lab Immunol 1995; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/28\">",
"      Caccamo DV, Keene CY, Durham J, Peven D. Fulminant rhabdomyolysis in a patient with dermatomyositis. Neurology 1993; 43:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/29\">",
"      Pirovino M, Neff MS, Sharon E. Myoglobinuria and acute renal failure with acute polymyositis. N Y State J Med 1979; 79:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/30\">",
"      Kim HW, Choi JR, Jang SJ, et al. Recurrent rhabdomyolysis and myoglobinuric acute renal failure in a patient with polymyositis. Nephrol Dial Transplant 2005; 20:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/31\">",
"      Gupta S, Blaivas M, Ike RW, Crofford LJ. Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases. J Clin Rheumatol 2001; 7:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/32\">",
"      Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62:2757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/33\">",
"      Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/34\">",
"      Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007; 17:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32632/abstract/35\">",
"      Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41:185.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5169 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32632=[""].join("\n");
var outline_f31_55_32632=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31738287\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25330957\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25330880\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25330888\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25330896\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25326274\">",
"      - Creatine kinase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25326281\">",
"      - Urine findings and myoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25330918\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25326295\">",
"      - Fluid and electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25331868\">",
"      - Acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25326302\">",
"      - Compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H300169955\">",
"      - Disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25326606\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86659023\">",
"      Indications for diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86659030\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H244425251\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H244425159\">",
"      When to suspect metabolic myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25326714\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25619306\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5169\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5169|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?22/63/23550\" title=\"algorithm 1\">",
"      Etiology of red urine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/905?source=related_link\">",
"      Approach to the metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26694?source=related_link\">",
"      Approach to the patient with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/33/10777?source=related_link\">",
"      Causes of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15369?source=related_link\">",
"      Crush-related acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24984?source=related_link\">",
"      Etiology of hypocalcemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36745?source=related_link\">",
"      Muscle enzymes in the evaluation of neuromuscular diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23928?source=related_link\">",
"      Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/59/22450?source=related_link\">",
"      Patient information: Rhabdomyolysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9879?source=related_link\">",
"      Viral myositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_55_32633="Overview of skin testing for allergic disease";
var content_f31_55_32633=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of skin testing for allergic disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/55/32633/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32633/contributors\">",
"     Hendrik Nolte, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32633/contributors\">",
"     Krzysztof Kowal, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32633/contributors\">",
"     Lawrence DuBuske, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/55/32633/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32633/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32633/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/55/32633/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/55/32633/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/55/32633/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of atopic disease has increased 10-fold in developed countries in the last two decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Almost 30 percent of Americans have symptoms of upper respiratory allergy, including up to 40 percent of children and 10 to 30 percent of adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/4\">",
"     4",
"    </a>",
"    ]. Inflammatory processes involving IgE (IgE-mediated allergies) account for the majority of clinically significant environmental, food, and medication allergies.",
"   </p>",
"   <p>",
"    There are three components to the diagnosis of an IgE-mediated allergic disorder. These are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Identifying the allergen, usually through a careful clinical history",
"     </li>",
"     <li>",
"      Demonstrating the presence of IgE specific to the allergen by skin testing or in vitro testing",
"     </li>",
"     <li>",
"      Establishing a causal relationship between exposure to the allergen and symptoms, either by history or with a challenge procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, allergy testing is an important element in the evaluation of allergic disease; however, by itself, it is",
"    <strong>",
"     not sufficient",
"    </strong>",
"    to make a diagnosis. A positive test (skin or in vitro) must be supported by an appropriate clinical history of reactivity and, in some cases, allergen challenge to confirm that the suspected allergen causes symptoms.",
"   </p>",
"   <p>",
"    This topic review will discuss general principles of skin testing, including indications, contraindications, factors influencing results, techniques, and accuracy. The two major methods of skin testing currently used, the",
"    <span class=\"nowrap\">",
"     <strong>",
"      prick/puncture",
"     </strong>",
"    </span>",
"    technique and the",
"    <strong>",
"     intradermal",
"    </strong>",
"    technique, are described. The use of skin testing to diagnose specific disorders is presented in the appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review includes the types of skin testing used in the diagnosis of IgE-mediated allergy. Other forms of skin testing, such as patch testing for contact dermatitis or atopy patch testing for eosinophilic gastrointestinal disorders, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link\">",
"     \"Overview of dermatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF SKIN TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing is the most rapid, sensitive, and cost effective testing modality for the detection of IgE-mediated disease. Results are obtained in less than an hour with minimal patient discomfort. However, there are some situations in which in vitro testing is preferable. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Contraindications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Skin testing and other diagnostic procedures in the field of allergy (eg, challenges) should be performed by specialists trained in the methods and interpretation of the test results. Any procedure that involves the deliberate exposure of a patient to a substance that may cause significant harm should be undertaken by someone with expertise in the emergency treatment of allergic reactions and anaphylaxis. In addition, because each type of allergy has unique characteristics and implications for the patient's health, an allergy expert can be an invaluable source of information for both the patient and the primary provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General approach to testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing may be very specific or more general, based upon the clinical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A focused approach is most appropriate for patients whose history",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      physical examination strongly indicates the identity of the specific offending allergen(s). As an example, a patient who developed urticaria and wheezing while taking penicillin would be evaluated with tests for IgE specific to penicillin and its immediate derivatives.",
"     </li>",
"     <li>",
"      A broader approach would be utilized for a patient with perennial rhinitis and asthma symptoms. In this setting, it would be appropriate to test with a selected panel of outdoor and indoor allergens pertinent to the geographical region:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Tree, grass, and weed pollens, with choices reflecting regional flora",
"     </li>",
"     <li>",
"      Molds, including Alternaria alternata, Penicillium notatum, Aspergillus fumigatus, and Cladosporium",
"     </li>",
"     <li>",
"      Dust mites, including Dermatophagoides pteronyssinus and Dermatophagoides farinae, and cockroach",
"     </li>",
"     <li>",
"      Animal danders, including cat pelt and dog epithelium",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A person with demonstrable IgE to a specific allergen is said to be \"sensitized\" to that allergen. Both skin testing and in vitro testing are used to demonstrate sensitization. However, a sensitized person is considered \"allergic\" to an allergen only if they react with representative symptoms when exposed to it.",
"   </p>",
"   <p>",
"    This distinction is made because not all sensitized patients will develop actual symptoms on exposure. With some food skin tests, for example, the percentage of people who react to a food for which they have skin tested positive can be as low as 50 percent. Thus, food challenge procedures are often necessary to clarify a patient's status. By comparison, the proportion of individuals with positive pollen skin tests who truly react is much higher; therefore, a positive skin test and a history of symptoms during the appropriate season are sufficient to make the diagnosis. As a result, the confirmation of reactivity is crucial to making an accurate diagnosis and each type of allergy must be approached individually.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathophysiologic mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing is a bioassay that detects the presence of allergen-specific IgE on a patient's mast cells. When allergen is introduced into the skin of a patient during skin testing, it comes into contact with cutaneous mast cells. Binding of the allergen occurs if the patient's mast cells are coated with IgE recognizing that specific allergen. If both IgE and allergen are present in sufficient quantities, then adjacent IgE molecules directed against the allergen may be cross-linked on the cell surface and initiate intracellular signaling.",
"   </p>",
"   <p>",
"    These events lead to mast cell activation, release of the contents of intracellular granules (degranulation), and the de novo generation of inflammatory mediators. Degranulation releases pre-formed vasoactive mediators and enzymes, such as histamine, tryptase, chymase, and carboxypeptidase. Histamine is the major mediator of the wheal and flare response, but other mediators (eg, prostaglandin D2) are also involved, as the size of the wheal does not correlate directly with the concentrations of histamine released [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical result of these cellular events is a positive skin test, or a transient \"wheal-and-flare\" reaction. This reaction consists of a central area of superficial skin edema (wheal) surrounded by erythema (flare). This pruritic reaction represents the immediate phase of the allergic reaction.",
"   </p>",
"   <p>",
"    Late phase reactions (LPRs) may develop at skin test sites in some individuals. These consist of deep tissue swelling, warmth, pruritus, and erythema beginning one to two hours after testing and resolving in 24 to 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. LPRs are mast cell-mediated and IgE dependent, although they do not predict symptoms on exposure and are not used in allergy diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing is useful in the diagnosis of a variety of IgE-mediated allergic disorders, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Allergic asthma, rhinitis, and conjunctivitis",
"      </strong>",
"      &mdash; Skin testing using panels of indoor and outdoor allergens is the primary diagnostic modality for these conditions and is well-validated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22362?source=see_link\">",
"       \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Food allergy",
"      </strong>",
"      &mdash; Skin testing is considered the primary diagnostic technique for a variety of food allergies, although in vitro testing is also well-validated for several childhood food allergies. In a small number of clinical settings, the results of skin testing may be accurate enough to circumvent the need for food challenges to confirm the diagnosis, although in many cases, challenge procedures are still needed if a definite diagnosis is required. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnostic evaluation of food allergy\", section on 'Accuracy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Some medication allergies",
"      </strong>",
"      &mdash; Skin testing is used in the diagnosis of IgE-mediated drug allergies; however, it has been validated and standardized only for the evaluation of penicillin allergy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=see_link\">",
"       \"Allergy to penicillins\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For allergies to other medications, including other antibiotics, biologicals, chemotherapy agents, insulin, and drugs used in anesthesia, skin testing is often used as part of the evaluation, but the significance of a positive or negative result is not as well-defined.",
"     </li>",
"     <li>",
"      <strong>",
"       Venom allergies",
"      </strong>",
"      &mdash; For allergy to the venoms of Hymenoptera species (wasps, honey bees, yellow jackets, hornet, imported fire ants, and others), skin testing is the diagnostic test of choice and is well-validated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14824?source=see_link\">",
"       \"Diagnosis of Hymenoptera venom allergy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7994?source=see_link\">",
"       \"Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Latex allergy",
"      </strong>",
"      &mdash; Skin testing can be used to evaluate for latex allergy, and biologically standardized extracts of latex allergen for skin prick testing are commercially available in the European Union and Canada, although not in the United States. Some allergists produce their own extracts for testing, although the concentration of allergens in these preparations can vary dramatically, and the protein content should be measured and standardized to avoid systemic reactions. The diagnosis of latex allergy is reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=see_link\">",
"       \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing should",
"    <strong>",
"     not",
"    </strong>",
"    routinely be performed in patients who are at high risk for an anaphylactic reaction to testing, have experienced a recent anaphylactic event, are taking medications that may interfere with the treatment of anaphylaxis, or have certain skin conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     High risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are at higher risk for an anaphylactic reaction in response to skin testing include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      People with poorly controlled asthma and reduced lung function",
"     </li>",
"     <li>",
"      People with clinical histories of severe reactions to minute amounts of allergen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with significant cardiovascular disease, including coronary artery disease and cardiac arrhythmias, and elderly patients may also present an enhanced risk potential for skin testing related to the adverse effects inherent in treating anaphylaxis in such patients.",
"   </p>",
"   <p>",
"    In vitro allergy testing should be the initial diagnostic modality in such patients, or in the case of uncontrolled asthma, skin testing can be performed after symptoms have been stabilized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recent anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An episode of anaphylaxis within the previous month is a contraindication to skin testing because it may yield falsely negative results. Anaphylaxis can render the skin temporarily non-reactive. Full restoration of reactivity can take two to four weeks. This is especially important in assessing patients who have had anaphylaxis from insect stings. In vitro allergen testing may be more reliable during this refractory period if immediate diagnosis is necessary, because free allergen-specific IgE in the serum is less affected by anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14824?source=see_link\">",
"     \"Diagnosis of Hymenoptera venom allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Presence of interfering medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta 2-antagonists and angiotensin converting enzyme antagonists may inhibit the management of anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .) Thus, in vitro assessment of serum antigen-specific IgE may be the safest method of testing for individuals who cannot discontinue these medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Skin conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with certain skin conditions, including dermographism, urticaria, and cutaneous mastocytosis, cannot be skin tested because false positive results are common. Skin test results are also difficult to interpret in patients with atopic dermatitis affecting the areas where testing is performed, both because of changes in skin cellularity and the application of topical medications. However, patients with atopic dermatitis can be skin tested normally if the tests are applied to unaffected areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FACTORS AFFECTING RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of skin testing are influenced by various factors, including medications and physiologic characteristics of the patient, as well as the reagents and devices used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's full medication list should be reviewed in advance of testing. Several types of medications can interfere with skin testing, although only some are routinely discontinued. Non-interfering allergy medications that can be continued are also discussed below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H1 antihistamines can suppress skin reactivity for one to seven days, depending upon the specific drug. The general practice is to discontinue these agents seven days prior to testing. First-generation, non-selective antihistamines (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ) generally suppress skin reactivity for one to three days, whereas second-generation antihistamines (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      ) may blunt skin tests for up to seven days. At the recommended doses, first-generation antihistamines (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      ) have a greater suppressive effect than second-generation antihistamines (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12934?source=see_link\">",
"       desloratadine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/11\">",
"       11",
"      </a>",
"      ]. If a negative or weak response to the positive histamine control is obtained on a patient who was recently taking antihistamines, a longer medication-free period and repeat testing is suggested.",
"     </li>",
"     <li>",
"      H2 receptor antagonists (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      ) are generally discontinued at least 48 hours before testing, as these medications may reduce the skin reactivity as well [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic glucocorticoids should not suppress skin tests. Even chronic and relatively high dose glucocorticoids (10 to 60 mg daily for two years) had minimal effect on skin prick testing in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/13\">",
"       13",
"      </a>",
"      ]. Therefore, skin testing may be performed in patients taking systemic glucocorticoids, although a negative or small response to the positive histamine control should raise the possibility of interference.",
"     </li>",
"     <li>",
"      The use of topical glucocorticoids for longer than one week can partially suppress responses to both allergens and histamine by locally reducing the number of skin mast cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. In this setting, skin testing should be performed on non-inflamed skin that has not been treated with topical agents.",
"     </li>",
"     <li>",
"      Inhaled or intranasal glucocorticoids do not affect the skin test response and may be taken by the patient prior to testing.",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      , an anti-IgE antibody used for asthma treatment, may depress skin reactivity for up to six months or longer after treatment has been discontinued.",
"     </li>",
"     <li>",
"      Some drugs prescribed for non-allergic diseases, including tricyclic antidepressants and phenothiazines, may block skin reactivity for up to two weeks. Muscle relaxants and antiemetic drugs can have antihistaminic properties that may also reduce skin test responses. Because many of these medications are difficult for patients to discontinue",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      have long half-lives, testing is often done despite them; however, interference must be considered if a weak or negative response is obtained. In such patients, assessment of allergen specific IgE in serum may be preferable.",
"     </li>",
"     <li>",
"      Decongestants, inhaled beta agonists, and cromolyn preparations do not affect skin testing.",
"     </li>",
"     <li>",
"      Limited data concerning topical calcineurin inhibitors are conflicting. No effect on skin testing was reported with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/17\">",
"       17",
"      </a>",
"      ]. However,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      (0.1 percent applied twice daily for two weeks) was found to significantly reduce allergen skin prick test results in a small group of children, without affecting responses to histamine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leukotriene receptor antagonists do not influence skin test responses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Physiologic variables",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several physiologic characteristics of the patient should be considered, although the effects of these factors are usually minor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The age of the patient can affect the results of skin testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/20\">",
"       20",
"      </a>",
"      ]. Skin testing can be performed in people of any age, although there are differences in responsiveness with age. Infants have smaller positive reactions to histamine and allergens, although clear positives can be obtained in very young children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/21\">",
"       21",
"      </a>",
"      ]. Skin reactivity increases gradually throughout childhood and plateaus in the mid-adolescent years. A gradual decline in reactivity is often seen after the age of 50 to 60 years, although skin testing is still accurate. Older adults may also respond less vigorously to histamine controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The skin of the forearm generally produces smaller wheals than the skin of the back. This effect is more pronounced with allergens than with histamine, although it is rarely of significant clinical consequence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/23\">",
"       23",
"      </a>",
"      ]. Performing testing on the arms has the advantage of allowing for the placement of a tourniquet proximal to the testing site in rare cases of anaphylaxis in response to testing. Tourniquets are applied in this setting to slow absorption of allergen into the central vasculature.",
"     </li>",
"     <li>",
"      The size of skin test reactions to some pollen antigens in sensitive patients may increase during the pollen season, although positive results are present throughout the year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Technical variables",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of skin testing can be influenced by the potency and quality of allergenic extracts, testing devices, and techniques. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15127?source=see_link\">",
"     \"An overview of allergen extracts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major inhalant allergens are well characterized and some are standardized in potency units (eg, grasses, dust mites, ragweed).",
"     </li>",
"     <li>",
"      Most commercially-available food extracts are not standardized. However, extracts of milk, eggs, peanuts, soy, fish, shellfish, and tree nuts are reliable. In contrast, commercial extracts of fruits and vegetables are sometimes inadequate because the responsible allergen may be labile and altered during processing. Thus, in the event of a negative skin test for these foods, or when there is suspicion that the allergenicity of the food depends on its preparation (raw vs cooked), the fresh food should be used for skin testing using the \"prick by prick\" method. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prick by prick testing'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Conversely, false positive results can arise from naturally occurring histamine and other vasoactive amines in some allergen extracts (ie, insect venoms, molds, foods) as extracts produced in the United States are not dialyzed to remove histamine, which may occur as a natural contaminant, or from cross-reactivity with clinically irrelevant proteins. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15127?source=see_link\">",
"       \"An overview of allergen extracts\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      An example of the latter phenomenon can occur in foods containing the profilin protein Bet v 2, which can cause positive skin tests to foods in birch allergic patients without symptoms of food allergy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/25\">",
"       25",
"      </a>",
"      ]. In the testing of non-standardized drug preparations, false positives can occur from irritating properties of the drug in question. If these issues are suspected, repeating the test in one or more volunteers to assure that the test is negative in others is sometimes required.",
"     </li>",
"     <li>",
"      The testing device used can influence the results, and the practitioner should consider the strengths and weaknesses of different devices when deciding which method to use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/26-29\">",
"       26-29",
"      </a>",
"      ]. This is of particular importance in research settings. As an example, multi-headed devices (those that allow for application of several antigens simultaneously) produce more false negatives than single headed devices, and the inner heads may produce weaker responses than the heads on the corners of the devices. However, these devices can be very useful when testing children by allowing rapid application of multiple antigens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/26,30-32\">",
"       26,30-32",
"      </a>",
"      ]. All staff who perform skin testing should be assessed for reproducibility of their skin test results using a given device and histamine positive and diluent negative controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ALLERGEN PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The allergens relevant to human allergic disease are usually either glycoproteins and lipoproteins from other living organisms, or in the case of some drug and occupational allergens, a combination of small chemical moieties conjugated (or \"haptenated\") to serum proteins. Allergens have in common the ability to trigger the formation of IgE in genetically susceptible individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/33\">",
"     33",
"    </a>",
"    ]. Hundreds of clinically significant allergens have been identified from tree, grass, and weed pollens, molds, dust mites, foods, parasites, animal danders, insect venoms, drugs, occupational chemicals, and other biologic materials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/34\">",
"     34",
"    </a>",
"    ]. At this time, the commercially-prepared allergens used in clinical practice are obtained almost exclusively from natural sources. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15127?source=see_link\">",
"     \"An overview of allergen extracts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases, the more important allergenic proteins from a given substance have been identified, cloned, sequenced, and produced through recombinant technology. However, recombinant allergens do not necessarily reproduce the clinical response observed to natural allergens. Allergens from natural sources are heterogeneous. Individual allergic patients can be sensitive to different allergens from the same source, and can even respond differently to isoallergens that are identical except for minor differences in primary amino acid composition or substituted side chains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/33\">",
"     33",
"    </a>",
"    ]. Thus, although recombinant allergens offer the advantages of being readily available and uniform in composition, they may not be appropriate in all settings. Recombinant allergens are used for both testing and treatment in Europe, although they are still limited to research applications in the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/21/10585?source=see_link\">",
"     \"Future diagnostic tools for food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CHOICE OF SKIN TEST METHOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two major methods of skin testing currently in use are the",
"    <span class=\"nowrap\">",
"     <strong>",
"      prick/puncture",
"     </strong>",
"    </span>",
"    technique and the",
"    <strong>",
"     intradermal",
"    </strong>",
"    technique. In most cases,",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    method is the appropriate initial procedure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       prick/puncture",
"      </span>",
"      method is the primary diagnostic method and is the most appropriate initial test, in the absence of contraindications. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"      <span class=\"nowrap\">",
"       Prick/puncture",
"      </span>",
"      testing is sensitive although not very specific; overall positive predictive accuracy is less than 50 percent if all types of allergens are considered together. Thus a positive prick test is consistent with possible allergy to that allergen, but allergy cannot be diagnosed until there is confirmation, either through convincing history or challenge, that symptoms develop upon exposure.",
"     </li>",
"     <li>",
"      Intradermal testing has much higher sensitivity but a higher rate of false positive results (ie, lower specificity). This type of testing carries a greater risk of inducing a systemic reaction, and therefore should",
"      <strong>",
"       only",
"      </strong>",
"      be performed",
"      <strong>",
"       after",
"      </strong>",
"      negative",
"      <span class=\"nowrap\">",
"       prick/puncture",
"      </span>",
"      testing. Intradermal tests that are positive for inhalant allergens, in the context of negative skin prick tests, have low positive predictive value for the presence of symptoms upon allergen exposure. One source of false positive results can be the presence of bioactive amines, including histamine, in many extracts, especially those derived from molds or foods.",
"      <br/>",
"      <br/>",
"      In contrast, the high sensitivity of intradermal tests is essential for the optimal detection of venom sensitivity, as failure to identify a venom allergy may lead to life threatening consequences. Intradermal testing is",
"      <strong>",
"       not",
"      </strong>",
"      currently used in the diagnosis of food or latex allergy in the United States, due to an unacceptably high rate of systemic reactions to testing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17656?source=see_link\">",
"       \"Anaphylaxis induced by subcutaneous allergen immunotherapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PRICK/PUNCTURE METHOD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    or epicutaneous method of skin testing involves application of droplets of 1:10 or 1:20",
"    <span class=\"nowrap\">",
"     weight/volume",
"    </span>",
"    allergen extract solutions on the volar surface of the forearm or upper back, after the skin has been cleaned with a 70 percent alcohol solution. Each droplet contains a single allergen extract, although for screening purposes, mixes of closely related allergens (eg, four tree pollens) are sometimes used. One of a number of commercially available test devices are then used to prick through the droplets of allergen. Tests should be placed at least two centimeters apart to avoid overlapping reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Prick by prick testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prick-by-prick testing is a variation of epicutaneous skin testing in which fresh food is used as a source of the allergen, instead of a commercially-prepared extract. This is often done to evaluate allergies to fruits, many of which occur only if the fruit is eaten in the raw form. To perform this, the food and the patient's skin are both cleaned, and the test device is used to prick first the food and then the patient's skin. If a positive test is obtained using this method, the test should be repeated on a non-allergic individual, to assure that the result is not a false positive irritant response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Controls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both a positive control of histamine dichloride (10",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    for epicutaneous use) and a negative control of diluent identical to that of the allergen extracts (usually glycerinated saline) should always be applied in order to verify that the patient's skin is normally responsive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Definition of a positive test",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive reaction appears as a raised wheal with surrounding erythema. A positive reaction is defined in one of two ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is defined most commonly as a wheal that is equal or larger in size to that associated with the histamine control, with the histamine control normally producing a wheal of at least three millimeters in diameter.",
"     </li>",
"     <li>",
"      Alternatively, a wheal diameter larger than three millimeters may be considered positive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Positive results are recorded by measuring the greatest diameter of both the wheal and the erythema (separate measurements for each) in millimeters, at 10 minutes for the histamine control, and at 15 to 20 minutes for the allergen extracts. For research purposes, a more precise measurement is usually used, in which the longest wheal diameter (D) and the diameter perpendicular to D (d) are measured. The result is then expressed as a mean (D +",
"    <span class=\"nowrap\">",
"     d)/2,",
"    </span>",
"    with a result of 3 mm or greater being considered positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin test reactions usually begin to resolve within 30 minutes. A permanent visual record of the results can be made by tracing the reactions with a fine-tipped marker and transferring them to clear tape, which is then placed on paper.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact sensitivity and specificity of skin prick testing are dependent on the allergens used as well as the different variables inherent in this bioassay. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Factors affecting results'",
"    </a>",
"    above.) For skin testing in general, the overall sensitivity is low, and often estimated at approximately 50 percent. Thus, a positive skin test only suggests the possibility of allergy. However, the negative predictive value of skin prick testing is very high and skin testing can exclude allergy with relative certainty. These characteristics are explained in more detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Positive results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive skin test to a particular allergen, taken alone, only indicates the presence of IgE specific to that allergen. It still must be demonstrated that the patient develops symptoms upon exposure to the allergen.",
"   </p>",
"   <p>",
"    When standardized inhalant extracts with high potency are used,",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    tests generally have high sensitivity and specificity (&gt;85 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/35,38\">",
"     35,38",
"    </a>",
"    ]. The diagnostic efficacy is lower for molds and certain foods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Allergen Preparation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A positive skin test in the absence of a relevant clinical history may be indicative of sub-clinical sensitization (ie, may be a true positive) that may eventually become clinically apparent, or it may be a false positive reaction.",
"   </p>",
"   <p>",
"    Compared with other allergens, the performance of inhalant extracts in the diagnosis of allergic rhinitis is superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/35,40,41\">",
"     35,40,41",
"    </a>",
"    ]. A large body of literature has examined this issue. The following are a few representative examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The performance of skin prick testing for identifying respiratory allergy was studied using 10 pollen allergens, two house dust mite allergens, and one cat allergen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/35\">",
"       35",
"      </a>",
"      ]. Testing was performed in 50 patients with asthma or allergic rhinitis (group 1), 50 without these conditions but with a positive immediate family history of the disorders (group 2), and 100 subjects without a personal or family history of asthma or allergic rhinitis (group 3). At least one positive test reaction (as defined by a mean wheal diameter of greater than or equal to 3 mm) was observed in 90, 46, and 29 percent of those in groups 1, 2, and 3, respectively, with accuracy based in part on the allergen. A positive reaction to the cat allergen was associated with a sensitivity, specificity, and diagnostic accuracy of 90 percent, when compared to the clinical history.",
"     </li>",
"     <li>",
"      In one study of 365 consecutive patients aged 12 years or older, the predictive value of history alone for seasonal allergic rhinitis was found to be 82 to 85 percent, and that of history in combination with",
"      <span class=\"nowrap\">",
"       prick/puncture",
"      </span>",
"      skin testing, 97 to 99 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skin testing for foods is much less reliable, and positive reactions that do not correlate to clinical reactivity are more common. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Negative results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The negative predictive accuracy of",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    skin testing is high. A negative skin test confirms the absence of an IgE-mediated reaction with greater than 95 percent accuracy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/42\">",
"     42",
"    </a>",
"    ]. As previously described, the negative predictive accuracy of food testing using commercial extracts is lower. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Factors affecting results'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     INTRADERMAL METHOD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intradermal (or intracutaneous) skin testing is performed by injection of 0.02 to 0.05 mL of a 1:500 to 1:1000",
"    <span class=\"nowrap\">",
"     weight/volume",
"    </span>",
"    allergen extract into the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/43\">",
"     43",
"    </a>",
"    ]. A 26 or 27 gauge needle, positioned at a 45 degree angle, is used to make a two to three mm \"bleb\" of extract intradermally. The technique is identical to that used to place the intradermal PPD test for tuberculosis.",
"   </p>",
"   <p>",
"    An intradermal negative control is included, in order to control for reactions in response to the injection method. A positive histamine control is not needed if reactivity to histamine has already been demonstrated by prick method; however, if required, histamine can be injected intradermally at a dilute concentration of 0.001",
"    <span class=\"nowrap\">",
"     mg/mL.",
"    </span>",
"   </p>",
"   <p>",
"    A positive intradermal result is a wheal of 5 mm or larger in most instances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/37,44\">",
"     37,44",
"    </a>",
"    ]. However, the 2008 practice parameter of the leading American allergy society states that &ldquo;any reaction larger than the negative control may indicate the presence of specific IgE antibody. Given the greater sensitivity and equivocal reproducibility of intradermal testing, however, small positive reactions may not be clinically significant&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/45\">",
"     45",
"    </a>",
"    ]. Evidence-based studies on standardized intracutaneous test grading are lacking. A survey of American board-certified allergists recently reported that 85 percent use the criterion of 3 mm greater than the negative control as a threshold for a positive intradermal test result.",
"   </p>",
"   <p>",
"    Intradermal tests are usually performed following",
"    <strong>",
"     negative",
"    </strong>",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    tests. Because they are approximately 100- to 1000-fold more sensitive, the starting test dose of intradermal extract solutions in patients with a preceding negative",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    test should range between 100 and 1000-fold more dilute than the",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    test solution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/6\">",
"     6",
"    </a>",
"    ]. Serial dilutions of progressively less dilute material may be required for the optimization of sensitivity for skin testing with venoms or drugs and to assess for potentially life threatening anaphylactic sensitization.",
"   </p>",
"   <p>",
"    End-point dilution technique &mdash; The technique of end-point dilution is a variant of intradermal testing that is used to identify the concentration of an extract that produces a reaction of a defined size. The more sensitive an individual is to a given extract, the lower the concentration required to produce a reaction of a given size. End-point dilution is performed by injecting a series of dilutions of an extract into a patient's skin, until a specific diameter wheal or flare is obtained. Uses include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Research studies of immunotherapy efficacy, because it provides a more precise measure of a patient's sensitivity",
"     </li>",
"     <li>",
"      Bioassays in commercial labs to standardize the strength of extracts.",
"     </li>",
"     <li>",
"      Evaluation of patients in whom nasal or bronchial challenges must be performed, as it can be used to assess the initial concentration for challenge.",
"     </li>",
"     <li>",
"      This technique is commonly used among otolaryngology practitioners in the diagnosis of allergy, however, use among allergy specialists is rare, having been largely replaced by",
"      <span class=\"nowrap\">",
"       prick/puncture",
"      </span>",
"      followed by standard intradermal testing with a single dilution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intradermal tests are more reproducible than",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    skin tests and are more sensitive. However, false-positive reactions are more common, and for some allergens, such as cat and grass allergens, have been demonstrated to add little to diagnostic accuracy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    False positives may be related to naturally-occurring histamine, endotoxins, and other skin irritants in some mold, venom, and inhalant extracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/49\">",
"     49",
"    </a>",
"    ]. Intracutaneous bleeding can be falsely interpreted as a positive reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6476491\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergy skin testing is considered a safe procedure, although it is not without risk. It is recommended that full emergency equipment and medications, (including epinephrine) be present for treatment of the rare, yet potentially life threatening anaphylactic event. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6477129\">",
"    <span class=\"h2\">",
"     Incidence of anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall rate of systemic reactions (SRs) to skin testing was estimated to be &lt;0.02 percent in a prospective study and approximately 0.003 percent in a retrospective study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/50\">",
"     50",
"    </a>",
"    ]. However, one prospective study found a much higher SRs rate of 3.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/51\">",
"     51",
"    </a>",
"    ]. A possible explanation for this difference is that intradermal testing may have been performed at a higher rate in this population. The large majority of SRs in this study were triggered by intradermal testing to aeroallergens. No severe SRs were reported.",
"   </p>",
"   <p>",
"    Overall, higher rates of SR have been reported following intradermal injection of food allergens and latex, and intradermal testing with these allergens is no longer recommended. In addition,",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    testing is always recommended prior to intradermal testing for aeroallergens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6477150\">",
"    <span class=\"h2\">",
"     Fatalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatal anaphylaxis as a result of allergen skin testing is exceedingly rare and nearly always associated with intradermal testing",
"    <strong>",
"     without",
"    </strong>",
"    prior",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6477019\">",
"    <span class=\"h2\">",
"     Anaphylaxis with prick/puncture testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a pediatric study, the rate of systemic reactions (SRs) to skin prick testing only (no intradermal testing) was 0.001 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/55\">",
"     55",
"    </a>",
"    ]. Risk factors for SRs in children included age &lt;one year and active eczema. Two cases of anaphylaxis were reported to skin prick testing with commercial fish extracts in children, both of whom had a history of asthma; one also had a history of atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/56\">",
"     56",
"    </a>",
"    ]. Skin prick testing using fresh foods has also caused rare anaphylactic reactions in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only known case of fatal anaphylaxis associated with skin prick testing occurred in an adult patient with food allergy and poorly controlled asthma, who was skin tested with 90 food allergens during a single testing session [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/55/32633/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"       \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=see_link\">",
"       \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/24/42370?source=see_link\">",
"       \"Patient information: Allergy skin testing (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The three components in the diagnosis of an IgE-mediated allergy are identification of the allergen, demonstration of IgE specific to that allergen, and confirmation that symptoms occur when the patient is exposed to the allergen. Skin testing is a diagnostic tool used in the second component. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A positive skin test, in isolation, is not sufficient to make a diagnosis of allergy, as it must also be demonstrated that the patient develops symptoms on exposure to that allergen. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin testing is a bioassay that detects the presence of allergen-specific IgE on the surface of a patient's cutaneous mast cells. Allergen is pricked into the skin and if allergen-specific IgE is present on the patient's mast cells, the cells are activated and produce localized pruritus, swelling, and erythema. Skin testing should be performed by an allergy expert, as there is a small but definite risk of inducing an allergic reaction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of skin testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The allergic diseases for which skin testing is useful in diagnosis include allergic asthma, rhinitis, and conjunctivitis, food allergy, some medication allergies, some venom allergies, and depending on the availability of testing reagents, latex allergy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin testing is contraindicated in patients who are at high risk for an anaphylactic reaction to testing, have experienced a recent anaphylactic event, are taking medications that may interfere with the treatment of anaphylaxis, or have certain skin conditions. Such patients should undergo in vitro allergy testing instead. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The results of skin testing are influenced by medications, physiologic characteristics of the patient, the device used, and the allergen extract used. Antihistamines must be discontinued prior to testing. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Factors affecting results'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The allergens relevant to human disease are mostly proteins from other living organisms that are able to trigger the formation of IgE in genetically susceptible individuals. Allergens for testing are obtained from natural sources and are heterogeneous. Efforts are underway to standardize their production around the world. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Allergen Preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two commonly used methods of skin testing for IgE-mediated disorders:",
"      <span class=\"nowrap\">",
"       prick/puncture",
"      </span>",
"      and intradermal.",
"      <span class=\"nowrap\">",
"       Prick/puncture",
"      </span>",
"      is performed first and is sensitive but not very specific. Intradermal testing is more sensitive, although false positives are common and it carries a higher risk of inducing an allergic reaction. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Choice of skin test method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Prick/puncture",
"      </span>",
"      skin testing has low specificity if all allergens are considered together. However, if standardized, high potency extracts are used (eg, pollens), sensitivity and specificity are both excellent. In addition, the negative predictive value of skin prick testing is very high and skin testing can exclude allergy with relative certainty. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prick/puncture method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intradermal tests are usually performed following",
"      <strong>",
"       negative",
"      </strong>",
"      <span class=\"nowrap\">",
"       prick/puncture",
"      </span>",
"      tests, and are approximately 100- to 1000-fold more sensitive. Intradermal testing is not performed in the diagnosis of food or latex allergy, due to an unacceptably high rate of both false positives and systemic reactions to testing. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Intradermal method'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/1\">",
"      Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999; 82:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/2\">",
"      Burr ML. Epidemiology of asthma. Monogr Allergy 1993; 31:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/3\">",
"      Burr ML, Butland BK, King S, Vaughan-Williams E. Changes in asthma prevalence: two surveys 15 years apart. Arch Dis Child 1989; 64:1452.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Allergy, Asthma, and Immunology. Overview of allergic diseases. Milwaukee, Wis: The Amercian Academy of Allergy, Asthma, and Immunology, Inc. 2000 The Allergy Report; Vol 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/5\">",
"      Horsmanheimo L, Harvima IT, Harvima RJ, et al. Histamine release in skin monitored with the microdialysis technique does not correlate with the weal size induced by cow allergen. Br J Dermatol 1996; 134:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/6\">",
"      Bernstein IL, Storms WW. Practice parameters for allergy diagnostic testing. Joint Task Force on Practice Parameters for the Diagnosis and Treatment of Asthma. The American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1995; 75:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/7\">",
"      Agarwal K, Zetterstr&ouml;m O. Diagnostic significance of late cutaneous allergic responses and their correlation with radioallergosorbent test. Clin Allergy 1982; 12:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/8\">",
"      Dolovich J, Hargreave FE, Chalmers R, et al. Late cutaneous allergic responses in isolated IgE-dependent reactions. J Allergy Clin Immunol 1973; 52:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/9\">",
"      Gr&ouml;nneberg R, Dahl&eacute;n SE. Interactions between histamine and prostanoids in IgE-dependent, late cutaneous reactions in man. J Allergy Clin Immunol 1990; 85:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/10\">",
"      Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol 2005; 115:S483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/11\">",
"      dos Santos RV, Magerl M, Mlynek A, Lima HC. Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines. Ann Allergy Asthma Immunol 2009; 102:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/12\">",
"      Kupczyk M, Kupry�� I, Boche��ska-Marciniak M, et al. Ranitidine (150 mg daily) inhibits wheal, flare, and itching reactions in skin-prick tests. Allergy Asthma Proc 2007; 28:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/13\">",
"      Des Roches A, Paradis L, Bougeard YH, et al. Long-term oral corticosteroid therapy does not alter the results of immediate-type allergy skin prick tests. J Allergy Clin Immunol 1996; 98:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/14\">",
"      Andersson M, Pipkorn U. Inhibition of the dermal immediate allergic reaction through prolonged treatment with topical glucocorticosteroids. J Allergy Clin Immunol 1987; 79:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/15\">",
"      Gradman J, Wolthers OD. Suppressive effects of topical mometasone furoate and tacrolimus on skin prick testing in children. Pediatr Dermatol 2008; 25:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/16\">",
"      Pipkorn U, Hammarlund A, Enerb&auml;ck L. Prolonged treatment with topical glucocorticoids results in an inhibition of the allergen-induced weal-and-flare response and a reduction in skin mast cell numbers and histamine content. Clin Exp Allergy 1989; 19:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/17\">",
"      Spergel JM, Nurse N, Taylor P, ParneixSpake A. Effect of topical pimecrolimus on epicutaneous skin testing. J Allergy Clin Immunol 2004; 114:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/18\">",
"      Simons FE, Johnston L, Gu X, Simons KJ. Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast. Ann Allergy Asthma Immunol 2001; 86:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/19\">",
"      Hill SL 3rd, Krouse JH. The effects of montelukast on intradermal wheal and flare. Otolaryngol Head Neck Surg 2003; 129:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/20\">",
"      Skassa-Brociek W, Manderscheid JC, Michel FB, Bousquet J. Skin test reactivity to histamine from infancy to old age. J Allergy Clin Immunol 1987; 80:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/21\">",
"      M&eacute;nardo JL, Bousquet J, Rodi&egrave;re M, et al. Skin test reactivity in infancy. J Allergy Clin Immunol 1985; 75:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/22\">",
"      Song WJ, Lee SM, Kim MH, et al. Histamine and allergen skin reactivity in the elderly population: results from the Korean Longitudinal Study on Health and Aging. Ann Allergy Asthma Immunol 2011; 107:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/23\">",
"      Nelson HS, Knoetzer J, Bucher B. Effect of distance between sites and region of the body on results of skin prick tests. J Allergy Clin Immunol 1996; 97:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/24\">",
"      Sin BA, Inceoglu O, Mungan D, et al. Is it important to perform pollen skin prick tests in the season? Ann Allergy Asthma Immunol 2001; 86:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/25\">",
"      Anhoej C, Backer V, Nolte H. Diagnostic evaluation of grass- and birch-allergic patients with oral allergy syndrome. Allergy 2001; 56:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/26\">",
"      Carr WW, Martin B, Howard RS, et al. Comparison of test devices for skin prick testing. J Allergy Clin Immunol 2005; 116:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/27\">",
"      Masse MS, Granger Vall&eacute;e A, Chiriac A, et al. Comparison of five techniques of skin prick tests used routinely in Europe. Allergy 2011; 66:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/28\">",
"      Engler DB, DeJarnatt AC, Sim TC, et al. Comparison of the sensitivity and precision of four skin test devices. J Allergy Clin Immunol 1992; 90:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/29\">",
"      Montalvo A, Mart&iacute;n S, Mesa A, et al. [Comparative study of 3 types of lancets for performing prick tests]. Allergol Immunopathol (Madr) 1996; 24:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/30\">",
"      Nelson HS, Kolehmainen C, Lahr J, et al. A comparison of multiheaded devices for allergy skin testing. J Allergy Clin Immunol 2004; 113:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/31\">",
"      Nelson HS, Lahr J, Buchmeier A, McCormick D. Evaluation of devices for skin prick testing. J Allergy Clin Immunol 1998; 101:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/32\">",
"      Dykewicz MS, Lemmon JK, Keaney DL. Comparison of the Multi-Test II and Skintestor Omni allergy skin test devices. Ann Allergy Asthma Immunol 2007; 98:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/33\">",
"      Hamilton RG, Adkinson NF Jr. 23. Clinical laboratory assessment of IgE-dependent hypersensitivity. J Allergy Clin Immunol 2003; 111:S687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/34\">",
"      Matsson P, Hamilton RG, Adkinson NF Jr, et al. Evaluation methods and analytical performance characteristics of immunologic assays for human immunoglobulin E (IgE) antibodies of defined allergen specificities. Wayne (PA): National Committee on Clinical Laboratory Standards (NCCLS). Approved guideline 1997; 17:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/35\">",
"      Adinoff AD, Rosloniec DM, McCall LL, Nelson HS. Immediate skin test reactivity to Food and Drug Administration-approved standardized extracts. J Allergy Clin Immunol 1990; 86:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/36\">",
"      Pepys J. Skin testing. Br J Hosp Med 1975; 14:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/37\">",
"      Ru&euml;ff F, Bergmann KC, Brockow K, et al. [Skin tests for diagnostics of allergic immediate-type reactions. Guideline of the German Society for Allergology and Clinical Immunology]. Pneumologie 2011; 65:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/38\">",
"      Tschopp JM, Sistek D, Schindler C, et al. Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in Adults. Allergy 1998; 53:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/39\">",
"      Sampson HA. Role of immediate food hypersensitivity in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1983; 71:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/40\">",
"      Crobach MJ, Hermans J, Kaptein AA, et al. The diagnosis of allergic rhinitis: how to combine the medical history with the results of radioallergosorbent tests and skin prick tests. Scand J Prim Health Care 1998; 16:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/41\">",
"      Bousquet J, Lebel B, Dhivert H, et al. Nasal challenge with pollen grains, skin-prick tests and specific IgE in patients with grass pollen allergy. Clin Allergy 1987; 17:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/42\">",
"      Sampson HA. Update on food allergy. J Allergy Clin Immunol 2004; 113:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/43\">",
"      Dolen WK. Skin testing techniques. Immunol Allergy Clin North Am 2001; 21:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/44\">",
"      Nadarajah R, Rechtweg J, Corey JP. Introduction to serial endpoint titration. Immunol Allergy Clin North Am 2001; 21:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/45\">",
"      Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol 2008; 100:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/46\">",
"      Lin SY, Mabry RL. Allergy practice in the academic otolaryngology setting: results of a comprehensive survey. Otolaryngol Head Neck Surg 2006; 134:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/47\">",
"      Nelson HS, Oppenheimer J, Buchmeier A, et al. An assessment of the role of intradermal skin testing in the diagnosis of clinically relevant allergy to timothy grass. J Allergy Clin Immunol 1996; 97:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/48\">",
"      Wood RA, Phipatanakul W, Hamilton RG, Eggleston PA. A comparison of skin prick tests, intradermal skin tests, and RASTs in the diagnosis of cat allergy. J Allergy Clin Immunol 1999; 103:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/49\">",
"      Williams PB, Nolte H, Dolen WK, et al. The histamine content of allergen extracts. J Allergy Clin Immunol 1992; 89:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/50\">",
"      Lin MS, Tanner E, Lynn J, Friday GA Jr. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy 1993; 71:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/51\">",
"      Bagg A, Chacko T, Lockey R. Reactions to prick and intradermal skin tests. Ann Allergy Asthma Immunol 2009; 102:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/52\">",
"      Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/53\">",
"      Bernstein DI, Wanner M, Borish L, et al. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004; 113:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/54\">",
"      Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001; 87:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/55\">",
"      Norrman G, F&auml;lth-Magnusson K. Adverse reactions to skin prick testing in children - prevalence and possible risk factors. Pediatr Allergy Immunol 2009; 20:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/56\">",
"      Pitsios C, Dimitriou A, Stefanaki EC, Kontou-Fili K. Anaphylaxis during skin testing with food allergens in children. Eur J Pediatr 2010; 169:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/55/32633/abstract/57\">",
"      Pitsios C. Generalized allergic reactions during skin testing. Pediatr Allergy Immunol 2010; 21:557.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5541 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32633=[""].join("\n");
var outline_f31_55_32633=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF SKIN TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General approach to testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathophysiologic mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      High risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recent anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Presence of interfering medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Skin conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FACTORS AFFECTING RESULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Physiologic variables",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Technical variables",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ALLERGEN PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CHOICE OF SKIN TEST METHOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PRICK/PUNCTURE METHOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Prick by prick testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Controls",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Definition of a positive test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Accuracy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Positive results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Negative results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      INTRADERMAL METHOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6476491\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6477129\">",
"      Incidence of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6477150\">",
"      Fatalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6477019\">",
"      Anaphylaxis with prick/puncture testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15127?source=related_link\">",
"      An overview of allergen extracts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17656?source=related_link\">",
"      Anaphylaxis induced by subcutaneous allergen immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14824?source=related_link\">",
"      Diagnosis of Hymenoptera venom allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/21/10585?source=related_link\">",
"      Future diagnostic tools for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=related_link\">",
"      Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/24/42370?source=related_link\">",
"      Patient information: Allergy skin testing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7994?source=related_link\">",
"      Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_55_32634="Electroanatomic mapping normal";
var content_f31_55_32634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63899%7ECARD%2F54163%7ECARD%2F57238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63899%7ECARD%2F54163%7ECARD%2F57238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electroanatomic voltage map from a normal subject",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The right ventricular (RV) voltage map in the right anterior oblique projection from a normal subject, is obtained using electroanatomic mapping. The colors represent the amplitude of the local unipolar electrogram and blue and purple indicated normal unipolar voltage values (&ge; 5 mV) throughout the RV.",
"    <div class=\"footnotes\">",
"     LA: left atrium; RA: right atrium.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Boulos, M, Lashevsky, I, Reisner, S, Gepstein, L. J Am Coll Cardiol 2001; 38:2020. Copyright &copy; 2001 American College of Cardiology.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Echocardiographic and electroanatomic mapping of the right ventricle in arrhythmogenic right ventricular dysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 451px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two-dimensional echocardiographic apical view of a patient with arrhythmogenic right ventricular dysplasia show severe enlargement of the right ventricle (RV) and right atrium (RA) (panel A). (B) The RV unipolar voltage maps, generated by electroanatomic mapping, are seen in the anteroposterior (panel B) and left anterior oblique views (panel C). There is extensive area of low voltage (red indicates &lt;2 mV) in the apex and anterolateral free wall of the RV, with the septum being spared (purple indicates &gt;5 mV).",
"    <div class=\"footnotes\">",
"     LA: left atrium; RVOT: RV outflow tract.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Boulos, M, Lashevsky, I, Reisner, S, Gepstein, L. J Am Coll Cardiol 2001; 38:2020. Copyright &copy; 2001 American College of Cardiology",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical electroanatomic map of infarcted myocardium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The electronatomic map of a patient with a myocardial infarction shows large regions of abnormal electromechanical activity and reduced local shortening (red, abnormally contracting regions with values &lt;4 percent). In contrast, a region in which function remains unhindered is a color-coded blue/purple, normal contractile function &gt;12 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the American College of Cardiology (Journal of the American College of Cardiology, 2001, 37:1590-7).",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32634=[""].join("\n");
var outline_f31_55_32634=null;
var title_f31_55_32635="RSV prophylaxis and CHD";
var content_f31_55_32635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Respiratory syncytial virus immunoprophylaxis for infants and young children with congenital heart disease*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Most likely to benefit from immunoprophylaxis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infants receiving medication to control heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infants with moderate to severe pulmonary hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infants with cyanotic heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Not indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Infants with hemodynamically insignificant heart disease:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Secundum atrial septal defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Small ventricular septal defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pulmonic stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Uncomplicated aortic stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mild coarctation of the aorta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Patent ductus arteriosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infants with lesions adequately corrected by surgery unless they continue to require medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infants with mild cardiomyopathy who are not receiving medical therapy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Palivizumab is the only RSV immunoprophylactic agent approved for infants with congenital heart disease.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112:1442.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32635=[""].join("\n");
var outline_f31_55_32635=null;
var title_f31_55_32636="Toxic optic neuropathies";
var content_f31_55_32636=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Toxins and drugs associated with an optic neuropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbon monoxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethylene glycol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perchloroethylene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobacco",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toluene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Styrene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        <p>",
"         Drug reactions (direct effect on the optic nerve)",
"        </p>",
"        <p>",
"         Antimicrobials",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clioquinol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloramphenicol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dapsone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethambutol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoniazid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodochlorhydroxyquinoline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Linezolid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immune modulators and suppressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclosporine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tacrolimus (FK506)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alpha interferon-2b",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cancer chemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-Fluorouracil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cisplatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carboplatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrosureas: BCNU (carmustine), CCNU (lomustine), and methyl-CCN (semustine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paclitaxel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vincristine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amiodarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorpropamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benoxaprofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cimetidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disulfiram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melatonin, sertraline hydrochloride (Zoloft), and a high-protein diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drug reactions (indirect effect on the optic nerve)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sildenafil (Viagra)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infliximab",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kerrison, JB. Optic neuropathies caused by toxins and adverse drug reactions. Opthalmol Clin North Am 2004; 17:481. Copyright &copy;2004 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32636=[""].join("\n");
var outline_f31_55_32636=null;
var title_f31_55_32637="Echo in mitral stenosis";
var content_f31_55_32637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68079%7ECARD%2F52663%7ECARD%2F68069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=25\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68079%7ECARD%2F52663%7ECARD%2F68069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=25\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Two-dimensional and Doppler echocardiography in mitral stenosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that echocardiography should be performed for the following reasons in patients with mitral stenosis:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Diagnosis of mitral stenosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Assessment of severity (mean gradient, mitral valve area, pulmonary artery pressure)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Assessment of concomitant valvular lesions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Assessment of mitral valve morphology to determine suitability for percutaneous mitral balloon valvotomy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Known mitral stenosis with changing signs and symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Assessment of the hemodynamic response of the mean gradient and pulmonary artery pressure by exercise Doppler echocardiography when there is a discrepancy between the the resting Doppler echocardiographic findings and clinical findings, symptoms, and signs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of usefulness of echocardiography in patients with mitral stenosis in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Reevaluation of asymptomatic patients who are clinically stable to assess pulmonary artery pressure every year with severe mitral stenosis, every one to two years with moderate mitral stenosis, and every three to five with mild mitral stenosis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Transesophageal echocardiography in mitral stenosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement that transesophageal echocardiography should be performed for",
"the following reasons in patients with mitral stenosis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess the presence of absence of left atrial thrombus and to further evaluate the severity of mitral regurgitation in patients being considered for percutaneous mitral balloon valvotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess mitral valve morphology and hemodynamics if transthoracic echocardiography provides suboptimal data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or",
"general agreement that transesophageal echocardiography is not useful",
"in patients with mitral stenosis in the following setting:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Transthoracic echocardiography provides satisfactory data on mitral valve morphology and hemodynamics",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Cardiac catheterization in mitral stenosis (MS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement that cardiac catheterization for hemodynamic evaluation is",
"useful in patients with MS in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess the severity of MS if noninvasive tests are not conclusive or there is a discrepancy between the results of noninvasive tests and clinical findings related to the severity of MS.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; When there is a discrepancy between mitral valve area and the Doppler-derived mean gradient; catheterization should include left ventriculography to evaluate the severity of mitral regurgitation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or",
"opinion is in favor of usefulness of cardiac catheterization for",
"hemodynamic evaluation in patients with MS in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess the exercise-induced hemodynamic response of the pulmonary artery and left atrial pressures when there is a discrepancy between clinical symptoms and hemodynamics at rest.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess the cause of severe pulmonary arterial hypertension if it is out of proportion to the severity of MS determined by noninvasive testing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or",
"general agreement that cardiac catheterization for hemodynamic",
"evaluation in patients with MS is not useful in in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess mitral valve hemodynamics when two-dimensional and Doppler echocardiographic findings are consistent with clinical findings.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32637=[""].join("\n");
var outline_f31_55_32637=null;
var title_f31_55_32638="Response criteria MF and SS";
var content_f31_55_32638=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F87757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F87757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Response criteria in mycosis fungoides and S&eacute;zary syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"6\">",
"        Response in specific tissues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Location",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Response",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"5\">",
"        Skin*",
"       </td>",
"       <td colspan=\"2\">",
"        CR",
"       </td>",
"       <td colspan=\"2\">",
"        100 percent clearance of skin lesions.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        PR",
"       </td>",
"       <td colspan=\"2\">",
"        50 to 99 percent clearance of skin disease from baseline without new tumors (T3) in patients with T1, T2, or T4 only skin disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        SD",
"       </td>",
"       <td colspan=\"2\">",
"        &lt;25 percent increase to &lt;50 percent clearance in skin disease from baseline without new tumors (T3) in patients with T1, T2, or T4 only skin disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        PD",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         &ge;25 percent increase in skin disease from baseline; OR",
"        </p>",
"        <p>",
"         New tumors (T3) in patients with T1, T2, or T4 only skin disease; OR",
"        </p>",
"        Loss of response: in those with complete or partial response, increase of skin score of greater than the sum of nadir plus 50 percent baseline score.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Relapse",
"       </td>",
"       <td colspan=\"2\">",
"        Any disease recurrence in those with complete response.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\" rowspan=\"5\">",
"        Lymph nodes",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        CR",
"       </td>",
"       <td colspan=\"2\">",
"        All lymph nodes are now &le;1.5 cm in greatest transverse (long axis) diameter by method used to assess lymph nodes at baseline or biopsy negative for lymphoma; in addition, lymph nodes that were N3 classification and &le;1.5 cm in their long axis and &gt;1 cm in their short axis at baseline, must now be &le;1 cm in their short axis or biopsy negative for lymphoma.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        PR",
"       </td>",
"       <td colspan=\"2\">",
"        Cumulative reduction &ge;50 percent of the SPD of each abnormal lymph node at baseline and no new lymph node &gt;1.5 cm in the diameter of the long axis or &gt;1 cm in the diameter of the short axis if the long axis is 1 to 1.5 cm diameter.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        SD",
"       </td>",
"       <td colspan=\"2\">",
"        Fails to attain the criteria for CR, PR, and PD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        PD",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         &ge;50 percent increase in SPD from baseline of lymph nodes; OR",
"        </p>",
"        <p>",
"         Any new node &gt;1.5 cm in the long axis or &gt;1 cm in the short axis if 1 to 1.5 cm in the long axis that is proven to be N3 histologically; OR",
"        </p>",
"        Loss of response: &gt;50 percent increase from nadir in SPD of lymph nodes in those with PR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Relapse",
"       </td>",
"       <td colspan=\"2\">",
"        Any new lymph node &gt;1.5 cm in the long axis in those with CR proven to be N3 histologically.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\" rowspan=\"5\">",
"        Viscera",
"       </td>",
"       <td colspan=\"2\">",
"        CR",
"       </td>",
"       <td colspan=\"2\">",
"        Liver or spleen or any organ considered involved at baseline should not be enlarged on physical exam and should be considered normal by imaging; no nodules should be present on imaging of liver or spleen; any post treatment mass must be determined by biopsy to be negative for lymphoma.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        PR",
"       </td>",
"       <td colspan=\"2\">",
"        &ge;50 percent regression in any splenic or liver nodules, or in measureable disease (SPD) in any organs abnormal at baseline; no increase in size of liver or spleen and no new sites of involvement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        SD",
"       </td>",
"       <td colspan=\"2\">",
"        Fails to attain the criteria for CR, PR, or PD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        PD",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         &gt;50 percent increase in size (SPD) of any organs involved at baseline; OR",
"        </p>",
"        <p>",
"         New organ involvement; OR",
"        </p>",
"        Loss of response: &gt;50 percent increase from nadir in the size (SPD) of any previous organ involvement in those with PR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Relapse",
"       </td>",
"       <td colspan=\"2\">",
"        New organ involvement in those with CR.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\" rowspan=\"5\">",
"        Blood",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        CR",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        B0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        PR",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        &gt;50 percent decrease in quantitative measurements of blood tumor burden from baseline in those with high tumor burden at baseline (B2).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        SD",
"       </td>",
"       <td colspan=\"2\">",
"        Fails to attain criteria for CR, PR, or PD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        PD",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         B0 to B2; OR",
"        </p>",
"        <p>",
"         &gt;50 percent increase from baseline and at least 5000 neoplastic cells/microL",
"         <sup>",
"          [1]",
"         </sup>",
"         ; OR",
"        </p>",
"        Loss of response: in those with PR who were originally B2 at baseline, &gt;50 percent increase from nadir and at least 5000 neoplastic cells/microL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Relapse",
"       </td>",
"       <td colspan=\"2\">",
"        Increase of neoplastic blood lymphocytes to &ge;B1 in those with CR.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\" colspan=\"6\">",
"        Global response score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Global score",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle2\">",
"        Skin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Nodes",
"       </td>",
"       <td class=\"subtitle2\">",
"        Blood",
"       </td>",
"       <td class=\"subtitle2\">",
"        Viscera",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CR",
"       </td>",
"       <td>",
"        Complete disappearance of all clinical evidence of disease",
"       </td>",
"       <td>",
"        CR",
"       </td>",
"       <td colspan=\"3\">",
"        All categories have CR/NI.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        PR",
"       </td>",
"       <td rowspan=\"2\">",
"        Regression of measurable disease",
"       </td>",
"       <td>",
"        CR",
"       </td>",
"       <td colspan=\"3\">",
"        All categories do not have a CR/NI and no category has a PD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PR",
"       </td>",
"       <td colspan=\"3\">",
"        No category has a PD and if any category involved at baseline, at least one has a CR or PR.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        SD",
"       </td>",
"       <td rowspan=\"2\">",
"        Failure to attain CR, PR, or PD representative of all disease",
"       </td>",
"       <td>",
"        PR",
"       </td>",
"       <td colspan=\"3\">",
"        No category has a PD and if any category involved at baseline, no CR or PR in any.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SD",
"       </td>",
"       <td colspan=\"3\">",
"        CR/NI, PR, SD in any category and no category has a PD.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        PD",
"       </td>",
"       <td>",
"        Progressive disease",
"       </td>",
"       <td colspan=\"4\">",
"        PD in any category.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Relapse",
"       </td>",
"       <td>",
"        Recurrence disease in prior CR",
"       </td>",
"       <td colspan=\"4\">",
"        Relapse in any category.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; SPD: sum of the maximum linear dimension (major axis) X longest perpendicular dimension (minor axis); NI: noninvolved.",
"     <br/>",
"     * Based on modified Severity Weighted Assessment Tool score.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     A biopsy of normal appearing skin is unnecessary to assign a complete response. However, a skin biopsy should be performed of a representative area of the skin if there is any question of residual disease (persistent erythema or pigmentary change) where otherwise a complete response would exist. If histologic features are suspicious or suggestive of mycosis fungoides/S&eacute;zary syndrome (see histologic criteria for early mycosis fungoides",
"     <sup>",
"      [2]",
"     </sup>",
"     ), the response should be considered a partial response only.",
"     <br/>",
"     &Delta; Whichever criterion occurs first.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Peripheral and central lymph nodes.",
"     <br/>",
"     &sect; As determined by absolute numbers of neoplastic cells/microL.",
"     <br/>",
"     &yen; If a bone marrow biopsy was performed at baseline and determined to unequivocally be indicative of lymphomatous involvement, then to confirm a global CR where blood assessment now meets criteria for B0, a repeat bone marrow biopsy must show no residual disease or the response should be considered a PR only.",
"     <br/>",
"     &Dagger; There is no PR in those with B1 disease at baseline as the difference within the range of neoplastic cells that define B1 is not considered significant and should not affect determination of global objective response.",
"     <br/>",
"     &dagger; It is recommended that not only the proportion of patients who achieve a response or an unfavorable outcome be calculated but a life table account for the length of the interval during which each patient is under observation also be generated.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87:4990.",
"      </li>",
"      <li>",
"       Sacks H, Chalmers TC, Smith H Jr. Randomized versus historical controls for clinical trials. Am J Med 1982; 72:233.",
"      </li>",
"     </ol>",
"     <br/>",
"     From: Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and S&eacute;zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29:2598-607. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32638=[""].join("\n");
var outline_f31_55_32638=null;
var title_f31_55_32639="MRI osteonecrosis glucocorticoids POF";
var content_f31_55_32639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI image of osteonecrosis in POF patient after glucocorticoids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI image of osteonecrosis of the R knee (black arrow) in a patient who had received glucocorticoids for treatment of premature ovarian failure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kalantaridou, SN, Braddock, DT, Patronas, NJ, Nelson, LM. Treatment of autoimmune premature ovarian failure. Hum Reprod 1999; 14:1777. Copyright &copy; 1999 Oxford University Press/Human Reproduction.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_55_32639=[""].join("\n");
var outline_f31_55_32639=null;
